Oramed Pharmaceuticals (ORMP) 10-K 6 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 06, 2024	Jun. 30, 2023
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Information [Line Items]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Entity File Number	001-35813
Entity Tax Identification Number	98-0376008
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 130,525,522
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1185 Avenue of the Americas
Entity Address, Address Line Two	Third Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10036
Entity Phone Fax Numbers [Line Items]
City Area Code	844
Local Phone Number	967-2633
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.012
Trading Symbol	ORMP
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		40,519,160

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Auditor [Table]
Auditor Name	Kesselman & Kesselman
Auditor Firm ID	1309
Auditor Location	Tel Aviv, Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 9,055	$ 40,464
Short-term deposits	95,279	111,513
Marketable securities		3,743
Investments at fair value	57,713
Prepaid expenses and other current assets	537	1,389
Total current assets	162,584	157,109
LONG-TERM ASSETS:
Long-term deposits	7	7
Investments at fair value	51,035
Marketable securities	1,807
Other non-marketable equity securities	3,524	2,700
Amounts funded in respect of employee rights upon retirement	27	24
Property and equipment, net	873	815
Operating lease right of use assets	694	987
Total long-term assets	57,967	4,533
Total assets	220,551	161,642
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,609	4,158
Short-term borrowings	51,013
Deferred revenues		1,340
Payable to related parties	325	1
Operating lease liabilities	267	247
Total current liabilities	53,214	5,746
LONG-TERM LIABILITIES:
Long-term deferred revenues	4,000	4,000
Employee rights upon retirement	28	21
Provision for uncertain tax position	11	11
Operating lease liabilities	342	647
Other liabilities	63	61
Total long-term liabilities	4,444	4,740
COMMITMENTS
EQUITY ATTRIBUTABLE TO COMPANY’S STOCKHOLDERS’:
Common stock, $ 0.012 par value (60,000,000 authorized shares as of December 31, 2023 and December 31, 2022; 40,338,979 and 39,563,888 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively)	485	476
Additional paid-in capital	320,892	314,417
Accumulated deficit	(157,556)	(163,081)
Total stockholders’ equity	163,821	151,812
Non-controlling interests	(928)	(656)
Total equity	162,893	151,156
Total liabilities and equity	$ 220,551	$ 161,642

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.012	$ 0.012
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	40,338,979	39,563,888
Common stock, shares outstanding	40,338,979	39,563,888

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES	$ 1,340	$ 2,703
RESEARCH AND DEVELOPMENT EXPENSES	(8,971)	(27,639)
SALES AND MARKETING	287	(1,851)
GENERAL AND ADMINISTRATIVE EXPENSES	(8,425)	(13,811)
OPERATING LOSS	(15,769)	(40,598)
INTEREST EXPENSES (note 11b)	(2,037)
FINANCIAL INCOME (EXPENSES), NET (note 11a)	22,894	2,934
INCOME (LOSS) BEFORE TAX EXPENSES	5,088	(37,664)
TAX EXPENSES		(100)
NET LOSS (INCOME)	5,088	(37,764)
COMPANY’S STOCKHOLDERS	5,525	(36,561)
NON-CONTROLLING INTERESTS	(437)	(1,203)
NET INCOME (LOSS)	$ 5,088	$ (37,764)
BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.14	$ (0.94)
DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share)	$ 0.14	$ (0.94)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	40,315,068	38,997,649
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares)	40,566,901	38,997,649

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock		Additional paid-in capital	Accumulated deficit	Total stockholders’ equity	Non- controlling interests	Total
BALANCE at Dec. 31, 2021	$ 459		$ 292,514	$ (126,520)	$ 166,453	$ 157	$ 166,610
BALANCE (in Shares) at Dec. 31, 2021	38,158
SHARES ISSUED FOR SERVICES		[1]	22		22		22
SHARES ISSUED FOR SERVICES (in Shares)	3
ISSUANCE OF COMMON STOCK, NET	$ 15		11,485		11,500		11,500
ISSUANCE OF COMMON STOCK, NET (in Shares)	1,213
EXERCISE OF WARRANTS AND OPTIONS		[1]	62		62		$ 62
EXERCISE OF WARRANTS AND OPTIONS (in Shares)	39						4,500
STOCK-BASED COMPENSATION	$ 2		11,117		11,119		$ 11,119
STOCK-BASED COMPENSATION (in Shares)	151
STOCK-BASED COMPENSATION OF SUBSIDIARY						390	390
TAX WITHHOLDINGS RELATED TO STOCK-BASED COMPENSATION SETTLEMENTS			(783)		(783)		(783)
NET INCOME (LOSS)				(36,561)	(36,561)	(1,203)	(37,764)
BALANCE at Dec. 31, 2022	$ 476		314,417	(163,081)	151,812	(656)	$ 151,156
BALANCE (in Shares) at Dec. 31, 2022	39,564						39,563,888
SHARES ISSUED FOR SERVICES		[1]	9		9		$ 9
SHARES ISSUED FOR SERVICES (in Shares)	3
ISSUANCE OF COMMON STOCK, NET	$ 2		2,426		2,428		2,428
ISSUANCE OF COMMON STOCK, NET (in Shares)	193
STOCK-BASED COMPENSATION	$ 7		4,040		4,047		4,047
STOCK-BASED COMPENSATION (in Shares)	579
STOCK-BASED COMPENSATION OF SUBSIDIARY						165	165
NET INCOME (LOSS)				5,525	5,525	(437)	5,088
BALANCE at Dec. 31, 2023	$ 485		$ 320,892	$ (157,556)	$ 163,821	$ (928)	$ 162,893
BALANCE (in Shares) at Dec. 31, 2023	40,339						40,338,979
[1]Represents an amount of less than $1.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 5,088	$ (37,764)
Adjustments required to reconcile net income (loss) to net cash used in operating activities:
Depreciation	196	58
Gain from selling fixed assets		(13)
Exchange differences and interest on deposits and held to maturity bonds	(2,172)	(1,550)
Changes in fair value of investments	(16,392)	763
Stock-based compensation	4,212	11,509
Shares issued for services	9	22
Funds in respect of employee rights upon retirement	(3)
Accrued interest on short-term borrowings to maturity	1,463
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	852	268
Accounts payable, accrued expenses and related parties	(2,225)	(376)
Net changes in operating lease	8	(93)
Deferred revenues	(1,340)	(703)
Liability for employee rights upon retirement	7	(1)
Other liabilities	2	(38)
Total net cash used in operating activities	(10,295)	(27,918)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(254)	(496)
Proceeds from selling fixed assets		24
Purchase of short-term deposits	(91,369)	(151,700)
Purchase of long-term deposits		(5)
Long-term investments	(99,550)	(2,700)
Proceeds from long-term investments	5,000
Proceeds from redemption of short-term deposits	109,760	178,200
Proceeds from maturity of held to maturity securities	3,375	6,886
Funds in respect of employee rights upon retirement		2
Total net cash provided by (used in) investing activities	(73,038)	30,211
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	2,428	11,500
Proceeds from exercise of warrants and options		62
Loans received	99,550
Loans repaid	(50,000)
Tax withholdings related to stock-based compensation settlements		(783)
Total net cash provided by financing activities	51,978	10,779
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(54)	(64)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(31,409)	13,008
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	40,464	27,456
CASH AND CASH EQUIVALENTS AT END OF YEAR	9,055	40,464
(A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS:
Taxes paid		100
Interest paid	574
Interest received	5,156	1,844
(B) SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Recognition of operating lease right of use assets and liabilities		$ 730

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES: a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company,” unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. On July 30, 2019, the Subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited (the “Hong Kong Subsidiary”). As of December 31, 2023, the Hong Kong Subsidiary has no operations. On March 18, 2021, the Company entered into a license agreement (the “Oravax License Agreement”) with Oravax Medical Inc. (“Oravax”) and into a stockholders agreement (the “Stockholders Agreement”) with Akers Biosciences Inc., Premas Biotech Pvt. Ltd., Cutter Mill Capital LLC (“Cutter Mill”) and Run Ridge LLC (“Run Ridge”). According to the Stockholders Agreement, Oravax issued 1,890,000 shares of its capital stock to the Company, representing 63% of the issued and outstanding share capital of Oravax, on a fully diluted basis, as of the date of issuance. Consequently, Oramed consolidates Oravax in its consolidated financial statements since that time. On November 23, 2021, Oravax incorporated a wholly-owned subsidiary in Israel, Oravax Medical Ltd., which is engaged in research and development. Effective January 1, 2022, Oravax transferred its rights and obligations under the Oravax License Agreement to Oravax Medical Ltd. On January 11, 2023, the Company announced that the ORA-D-013-1 Phase 3 trial did not meet its primary or secondary endpoints. As a result, the Company terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial. As these results are considered a triggering event, the Company evaluated all of its long lived assets which include fixed assets and operating lease right-of-use assets in the first quarter of 2023 and concluded that no impairment was required. In 2023, the Company completed an analysis of the data from the ORA-D-013-1 Phase 3 trial and found that subpopulations of patients with pooled specific parameters, such as body mass index (BMI), baseline HbA1c and age, responded well to oral insulin. These subsets exhibited an over 1% placebo adjusted, statistically significant, reduction in HbA1c. Based on this analysis, the Company is working on a protocol for a new Phase 3 clinical trial to be submitted to the U.S. Food and Drug Administration (the “FDA”). Concurrently, the Company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for the Company’s stockholders. 2) Development and liquidity risks The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Following the termination of the ORA-D-013-1 and ORA-D-013-2 Phase 3 trials, the Company’s research and development activities have been significantly reduced while it conducted a strategic review process. As a result, the Company is currently incurring lower research and development and sales and marketing expenses. The Company is working on a protocol for a new Phase 3 clinical trial to be submitted to the FDA. Concurrently, the Company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities. Based on the Company’s current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that the Company will not need additional funds prior to such time. If there are unexpected increases in its operating expenses, the Company may need to seek additional financing during the next 12 months. The Company may also need additional funds to realize the decisions made as part of its strategic review process. The Company cannot predict the outcome of these activities. On August 7, 2023, the Company entered into a Stock Purchase Agreement, as subsequently amended on August 9, 2023 and August 21, 2023, (the “Sorrento SPA”), with Sorrento Therapeutics, Inc. (“Sorrento”), to acquire certain equity securities of Scilex Holding Company (“Scilex”), owned by Sorrento (the “Purchased Securities”), for a purchase price of $105,000. Sorrento and its affiliated debtor, Scintilla Pharmaceuticals, Inc. (“Scintilla” and together with Sorrento, the “Debtors”) are in Chapter 11 bankruptcy proceedings. On August 9, 2023, the Company entered into a Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement (the “Senior DIP Loan Agreement”) with the Debtors in the principal amount of $100,000, which included a non-refundable closing fee of $450 paid in full out of the proceeds. This amount was subsequently drawn in full by the Debtors and was intended to be used by the Company as a credit for the consideration for the Purchased Securities, with an additional $5,000 in cash to be paid by the Company at closing. Thereafter, the Company and Sorrento continued discussions and negotiations relating to the sale contemplated under the Sorrento SPA. On September 21, 2023, the Company entered into and consummated the transactions contemplated by a Securities Purchase Agreement (the “Scilex SPA”) with Scilex and Acquiom Agency Services LLC. Pursuant to the Scilex SPA, in exchange for Scilex assuming outstanding obligations of Sorrento under the Senior DIP Loan Agreement (the “DIP Assumption”) and for the ability to credit the amounts assumed under the DIP Assumption in exchange for certain equity securities of Scilex owned by Sorrento, Scilex (i) issued to the Company (A) a Senior Secured Promissory Note due 18 months from the date of issuance in the principal amount of $101,875 (the “Note”), which includes accrued and unpaid interest of $875 under the Senior DIP Loan Agreement and $1,000 of fees added to the principal amount of the Note, (B) the Closing Penny Warrant (as defined herein), and (C) the Subsequent Penny Warrants (as defined herein), and (ii) caused the Transferred Warrants (as defined herein) to be transferred to the Company. For further details, see note 4. On August 8, 2023, the Company borrowed an aggregate of $99,550 pursuant to loan agreements from Israel Discount Bank Ltd. For further details, see note 7. b. Basis of presentation The consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation and to the investments at fair value (for further details, see note 4). d. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate. e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. f. Cash equivalents The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: December 31, 2023 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 297 - - 297 Entera 70 - - 70 Transferred Warrants (see note 4) 1,440 - - 1,440 Closing Penny Warrant (see note 4) - 9,180 - 9,180 Subsequent Penny Warrants (see note 4) - - 6,502 6,502 The Note (see note 4) - - 93,066 93,066 $ 1,807 $ 9,180 $ 99,568 $ 110,555 December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 352 - - 352 Entera 85 - - 85 $ 437 $ - $ - $ 437 The fair value of the investment in non-marketable equity securities as presented in note 5 was based on a Level 3 measurement. As of December 31, 2023, the carrying amounts of cash equivalents, short-term deposits, Short-Term Borrowings (as defined in note 7) and accounts payable approximate their fair values due to the short-term maturities of these instruments. As of December 31, 2022, the carrying amounts of cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities of these instruments. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value. h. Marketable securities 1. Equity securities The Company measured the securities (investments in equity securities of DNA GROUP (T.R.) Ltd. (“DNA”), Entera Bio Ltd. (“Entera”) and the Transferred Warrants) at fair value, with changes in fair value recognized in earnings. 2. Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. i. Other non-marketable equity securities The Company also invested in non-marketable equity securities, through an investment in a privately held company. This equity investment does not have a readily determinable fair value. The investment is measured under the measurement alternative in Accounting Standards Codification (“ASC”) 321 “Investments – Equity Securities” to the extent such an investment is not subject to consolidation or the equity method. Under the measurement alternative, this equity investment is carried at cost, less any impairment, adjusted for changes resulting from observable price changes in transactions for an identical or similar investment of the same issuer. The investment would be impaired in accordance with the provisions of ASC 820 “Fair Value Measurement” if, based on a qualitative assessment of impairment indicators, the fair value of the investment is less than its carrying amount. If considered impaired, the difference between the carrying amount and fair value would be recorded in the consolidated statement of operations. For further details, see note 5. j. Investments, at fair value The Company invested in the Note and received Penny Warrants issued by Scilex (see note 4), for which it has elected the fair value option. Under the Fair Value Option Subsections of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report financial assets at fair value on an instrument-by-instrument basis. Changes in fair value are recorded under financial income, net and include interest income on the Note. Alongside the Note and the Penny Warrants, Scilex issued to the Company the Transferred Warrants. The Transferred Warrants meet the definition of a derivative under ASC 815 “Derivatives and Hedging,” and therefore will also be measured at fair value. Changes in the fair value of the Warrants are recorded under financial income, net. k. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits, which are deposited in major financial institutions, marketable securities, and the Note (as defined herein). The Company is of the opinion that the credit risk in respect of these balances is remote, except for the Note (as defined herein) for which the credit risk is reflected in its fair value measurement (for further details, see note 4). l. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 12. Taxes that would apply in the event of disposal of investments in the Israeli subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within 12 months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses. m. Revenue recognition HTIT On November 30, 2015, the Company entered into a Technology License Agreement, with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”). As of December 31, 2023, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through December 31, 2023, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, of which $1,340 was recognized in the twelve month period ended December 31, 2023, and deferred the remaining amount of $2,000, which is presented as long-term deferred revenues on the consolidated balance sheet. Medicox On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 8c. Under ASC 606 “Revenue from Contracts with Customers,” the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer. The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts. The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company during the year ended December 31, 2022 and is currently presented under long-term deferred revenues. It also contains variable consideration of contractual milestone payments and sales-based royalties. The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of December 31, 2023, this support has not commenced, and no revenue was recognized from the Medicox License Agreement. If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage, going forward. The Company notes that its Phase 3 trial did not meet its primary or secondary endpoints (see note 1a.1). If Medicox chooses to terminate the agreement as a result of the outcome of the Phase 3 trials, the Company will accelerate revenue recognition and recognize it at such time. n. Research and development Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Clinical Research Organizations (“CROs”), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately. o. Stock-based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options and restricted stock units (“RSUs”) with an exercise price using the Black Scholes pricing model, for stock options and RSUs with market conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees’ exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense is not reversed if the market conditions are not satisfied. The Company elects to account for forfeitures as they occur. p. Earnings (loss) per common share Basic net earnings (loss) per common share are computed by dividing the net earnings (loss) attributable to stockholders for the period by the weighted average number of shares of common stock outstanding for each period, including vested RSUs. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for the year ended December 31, 2022. For the diluted earnings per share calculation for the year ended December 31, 2023, the weighted average number of shares outstanding during the year is adjusted for the potential dilution that could occur in connection with employee share-based payment, using the treasury stock method. The weighted average number of stock options, warrants, and RSUs that has been excluded from the calculation of the diluted income per share as of December 31, 2023 was 1,227,506 shares. The weighted average number of stock options, warrants and RSUs excluded from the calculation of diluted net loss was 3,356,203 for the year ended December 31, 2022. q. Leases The Company leases real estate and cars for use in its operations, which are classified as operating leases. In addition to rent, the leases may require the Company to pay directly for fees, insurance, maintenance and other operating expenses. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right of use assets and operating lease liabilities in the consolidated balance sheets. Right of use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. Lease expenses are recognized on a straight-line basis over the lease term. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities but recognizes lease expenses over the lease term on a straight line basis. The Company also elected the practical expedient to not separate lease and non-lease components for all of its leases. Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company’s lease agreements have remaining lease terms ranging from 1 year to 4 years. Some of these agreements include options to extend the leases for up to an additional 5 years and some include options to terminate the leases immediately. See also note 8e. r. New accounting pronouncements Recently adopted accounting pronouncements In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) “Financial Instruments—Credit Losses—Measurement of Credit Losses on Financial Instruments.” This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning after December 15, 2022, including interim periods within that year. The Company adopted the provisions of this update as of January 1, 2023, with no material impact on its consolidated financial statements. Recently issued accounting pronouncements, not yet adopted In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures.” This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280 “Segment Reporting”. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

Short-Term Deposits

Short-Term Deposits	12 Months Ended
	Dec. 31, 2023
Short-Term Deposits [Abstract]
SHORT-TERM DEPOSITS	NOTE 2 - SHORT-TERM DEPOSITS: Composition December 31, 2023 2022 Annual Amount Annual Amount Dollar deposits 6.35-6.81 % $ 95,279 0.93-6.81 % $ 111,513

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2023
Marketable Securities [Abstract]
MARKETABLE SECURITIES	NOTE 3 - MARKETABLE SECURITIES: a. Composition: The Company’s marketable securities include investments in equity securities of DNA, Entera and the Transferred Warrants (as defined herein; for further details regarding the Transferred Warrants, see note 4). As of December 31, 2022, marketable securities also included held to maturity securities. December 31, 2023 2022 Short-term: DNA (see b below) $ - $ 352 Entera (see c below) - 85 Held to maturity securities (see d below) - 3,306 $ - $ 3,743 Long-term: DNA (see b below) $ 297 $ - Entera (see c below) 70 - Transferred Warrants (see note 4) 1,440 - $ 1,807 $ - b. DNA DNA’s ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date. During the years ended December 31, 2023 and 2022, the Company did not sell any of DNA’s ordinary shares. As of December 31, 2023, the Company owns approximately 1.4% of DNA’s outstanding ordinary shares. The cost of the securities as of both December 31, 2023 and 2022 was $595. c. Entera Entera ordinary shares have been traded on the Nasdaq Capital Market since June 28, 2018. The Company measures the investment at fair value from such date, since it has a readily determinable fair value (prior to such date the investment was accounted for as a cost method investment (amounting to $1)). d. Held to maturity securities The Company did not have any held to maturity securities as of December 31, 2023. The amortized cost and estimated fair value of held-to-maturity securities as of December 31, 2022, are as follows: December 31, 2022 Amortized Gross Estimated Average Short-term: Commercial bonds $ 3,258 $ (82 ) $ 3,176 1.07 % Accrued interest 48 - 48 $ 3,306 $ (82 ) $ 3,224

Investments, at Fair Value

Investments, at Fair Value	12 Months Ended
	Dec. 31, 2023
Investments, at Fair Value [Abstract]
INVESTMENTS, AT FAIR VALUE	NOTE 4 - INVESTMENTS, AT FAIR VALUE: Scilex Transaction On September 21, 2023 (the “Closing Date”), the Company entered into and consummated the transactions (collectively, the “Transaction”) contemplated by the Scilex SPA with Scilex and Acquiom Agency Services LLC. Pursuant to the Scilex SPA, in exchange for the DIP Assumption and for the ability to credit the amounts assumed under the DIP Assumption in exchange for certain equity securities of Scilex owned by Sorrento, Scilex (i) issued to the Company (A) the Note, (B) a warrant to purchase up to an aggregate of 4,500,000 shares of common stock of Scilex, par value $0.0001 per share (“Scilex Common Stock”), with an exercise price of $0.01 per share and containing certain restrictions on exercisability (the “Closing Penny Warrant”), and (C) warrants to purchase up to an aggregate of 8,500,000 shares of Scilex Common Stock (the “Subsequent Penny Warrants” and together with the Closing Penny Warrant, the “Penny Warrants”), each with an exercise price of $0.01 per share and each with certain restrictions on exercisability, and (ii) caused certain outstanding warrants to purchase up to an aggregate of 4,000,000 shares of Scilex Common Stock with an exercise price of $11.50 per share to be transferred to the Company (the “Transferred Warrants” and together with the Penny Warrants, the “Warrants”). In addition, on the Closing Date, Scilex reimbursed $1,910 of the Company’s Transaction expenses pursuant to the Scilex SPA. Pursuant to the terms of the Scilex SPA, Scilex agreed to certain restrictions on additional issuances of equity securities. In connection with the Transaction, the Company and Sorrento mutually agreed to terminate the Sorrento SPA and to release all claims the Company and Sorrento may have against one another, and Scilex completed the acquisition of the Purchased Securities. The Note The principal of the Note issued on September 21, 2023 is $101,875, which includes accrued and unpaid interest of $875 under the Senior DIP Loan Agreement and $1,000 of fees added to the principal amount of the Note. The Note matures on March 21, 2025 or upon an uncured event of default, subject to certain mandatory prepayments, and bears interest at a rate per annum equal to Term SOFR (as defined in the Note) plus 8.5% (subject to a Term SOFR floor of 4.0%), to be paid in-kind, by being capitalized and added to the principal amount of the Note on a monthly basis. The Scilex SPA provides for principal payments of (i) $5,000 on December 21, 2023, (ii) $15,000 on March 21, 2024, and (iii) $20,000 on each of June 21, 2024, September 21, 2024, and December 21, 2024, and for the entire remaining principal balance of the Note to be paid on March 21, 2025. If the Note is not repaid in full on or prior to March 21, 2024, an exit fee equal to approximately $3,056 shall be payable upon repayment of the Note in full. The Note constitutes senior secured indebtedness of Scilex and is guaranteed by all existing or future formed, direct and indirect, domestic subsidiaries of Scilex and is secured by a first priority security interest in and liens on all of the assets of Scilex, subject to customary and mutually agreed permitted liens and except for certain specified exemptions. Mandatory prepayments under the Note are required following the earlier of (a) April 1, 2024 and (b) the date upon which certain of Scilex’s outstanding indebtedness are repaid in full. Mandatory prepayments may be triggered by certain future equity and debt issuances by Scilex. Voluntary prepayments may be made at Scilex’s discretion; provided that, if made prior to the one-year anniversary of the Closing Date, Scilex will also be required to pay a 50% interest make-whole on the portion of the Note so prepaid. The Note includes customary events of default, upon which the Note will bear interest at a default rate of Term SOFR plus 15.0%, which shall be payable in-kind, by being capitalized and added to the principal amount of the Note on a monthly basis. If the Note is accelerated upon an event of default, Scilex is required to repay the principal amount of the Note at a mandatory default rate of 125% of such principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Note). Until the obligations under the Note are repaid in full, the Company has the right to designate one non-voting observer to attend meetings of the board of directors and committees of Scilex and its subsidiaries. Pursuant to the terms of the Scilex SPA, the Company received the first principal payment of $5,000 on December 21, 2023. Closing Penny Warrant The Closing Penny Warrant will be exercisable upon the earliest of (i) March 14, 2025, (ii) the date on which the Senior Secured Note has been repaid in full and (iii) the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date (i.e., September 21, 2028). For purposes of the Closing Penny Warrant (as well as the Subsequent Penny Warrants), the Management Sale Trigger Date is generally the first date that either Dr. Henry Ji, Scilex’s Executive Chairperson, or Mr. Jaisim Shah, Scilex’s Chief Executive Officer and President and a member of Scilex’s Board of Directors, engages in certain sales or other similar transfers of shares of Common Stock or other of the Issuer’s or any of its subsidiaries’ securities, subject to certain exceptions in connection with financings or similar transactions. The exercise price of the Closing Penny Warrant is $0.01 per share, subject to adjustment. Subsequent Penny Warrants Scilex issued four Subsequent Penny Warrants to the Company, each for 2,125,000 shares of Scilex Common Stock, one of which shall vest and become exercisable on the date that is the later of (i) each of March 19, 2024, June 17, 2024, September 15, 2024 or December 14, 2024 (the “Subsequent Penny Warrant Vesting Date”) and (ii) the earliest of (A) March 14, 2025, (B) the date on which the Senior Secured Note has been repaid in full and (C) the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Senior Secured Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Senior Secured Note is repaid in full. The Company may exercise the Penny Warrants by means of a “cashless exercise.” The Penny Warrants may not be exercised if the Company, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Scilex Common Stock outstanding immediately after giving effect to such exercise; provided, that the Company may increase or decrease such limitation upon 61 days’ prior notice to Scilex. Transferred Warrants The Transferred Warrants are listed on the Nasdaq Capital Market, have an exercise price of $11.50 per share, are fully exercisable and expire on November 10, 2027. The Company accounted for the Transferred Warrants as derivatives measured at fair value. The Company elected the fair value option for the Note and the Penny Warrants in order to reduce operational complexity of bifurcating embedded derivatives. Changes in fair value are recorded under financial income, net and include interest income on the Note. The valuation was performed, as of December 31, 2023, based on several scenarios which some of them took into account a partial or full early repayment of the Note. Each scenario took into consideration the present value of the Note’s cash flows (including the exit fee and the prepayment premium) and the Warrants’ value. The total value of the Transaction (and of each of its components) was valued on a weighted average of the different scenarios. The discount rate of the Note was based on the B- rating Zero curve in addition to a risk premium which takes into account the credit risk of Scilex and ranged between 51.92% to 52.84%. The fair value of the Transferred Warrants was based on their closing price on the Nasdaq Capital Market. The fair value of the Penny Warrants was calculated based on the closing price of the Scilex stock on the Nasdaq Capital Market, taking into account several scenarios which assume a partial or full early repayment of the Note, when applicable. On the Closing Date, the fair value of the Transaction was $101,875. As of December 31, 2023, the fair value of the Transaction was $110,188, split between the Note ($93,066, of which $57,713 is presented under short-term investments at fair value and $35,353 is presented under long-term investments at fair value), the Closing Penny Warrant ($9,180), the Subsequent Penny Warrants ($6,502), both presented under long-term investments at fair value and the Transferred Warrants ($1,440) presented under long-term marketable securities. This resulted in a gain of $15,638, attributed mainly to the change in fair value of the Note and the Warrants. The difference between the Note’s fair value and aggregate unpaid principal balance (which includes interest payable on maturity) is $7,801.

Other Non-Marketable Equity Sec

Other Non-Marketable Equity Securities	12 Months Ended
	Dec. 31, 2023
Other Non-Marketable Equity Securities [Abstract]
OTHER NON-MARKETABLE EQUITY SECURITIES	NOTE 5 - OTHER NON-MARKETABLE EQUITY SECURITIES: On August 26, 2022, the Company entered into a stock purchase agreement with Diasome Pharmaceuticals, Inc. (“Diasome”), a privately-held company, pursuant to which the Company purchased shares of Series B preferred stock of Diasome for an aggregate purchase price of approximately $2,700. Following the purchase, the Company holds less than 5% of the issued and outstanding stock of Diasome. The stock purchase agreement provides the Company with the option to purchase additional preferred shares of stock on a pro rata basis at similar terms to the terms and conditions of the current round contingent upon Diasome achieving certain milestones. The Company’s non-marketable equity securities are an investment in a company without a readily determinable fair value. The Company accounts for this investment under the measurement alternative in ASC 321, whereby the equity investment is recorded at cost, less impairment. The carrying amount is subsequently remeasured to its fair value in accordance with the provisions of ASC 820 when observable price changes occur as of the date the transaction occurred, or it is impaired. Any adjustments to the carrying amount are recorded in the statements of comprehensive income (loss). During the year ended December 31, 2023, the Company recorded an $824 increase in value due to the closing in June 2023 of a Series C preferred investment round in Diasome. The change was recorded using the transaction price of similar securities issued by Diasome, adjusted for contractual rights and obligations of the securities held by the Company.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Composition: December 31, 2023 2022 Accounts payable $ 551 $ 2,175 Payroll and related accruals 453 529 Institutions - 11 Accrued liabilities 605 1,443 $ 1,609 $ 4,158

Short-Term Borrowings

Short-Term Borrowings	12 Months Ended
	Dec. 31, 2023
Short-Term Borrowings [Abstract]
SHORT-TERM BORROWINGS	NOTE 7 - SHORT-TERM BORROWINGS: On August 8, 2023, the Company borrowed an aggregate of $99,550 pursuant to loan agreements from Israel Discount Bank Ltd. (the “Short-Term Borrowings”). The Short-Term Borrowings mature on dates ranging from August 11, 2023 to May 24, 2024, bear interest ranging from 6.66% to 7.38%, and are secured by certificates of deposits issued by Israel Discount Bank Ltd. having an aggregate face amount of $99,550. The net proceeds of the Short-Term Borrowings were used to fund the Transaction (for further details, see note 4). The Short-Term Borrowings are paid in one payment of principal and interest at each respective maturity. As of December 31, 2023, $50,000 was repaid under the Short-Term Borrowings. The aggregate remaining annual principal payments on debt until maturity are as follows: Annual 2024 49,550 Total $ 49,550

Commitments

Commitments	12 Months Ended
	Dec. 31, 2023
Commitments [Abstract]
COMMITMENTS	NOTE 8 - COMMITMENTS: a. In March 2011, the Subsidiary sold shares of its investee company, Entera, to DNA, retaining 117,000 ordinary shares (after giving effect to a stock split by Entera in July 2018). In consideration for the shares sold to DNA, the Company received, among other payments, ordinary shares of DNA (see also note 3). As part of this agreement, the Subsidiary entered into a patent transfer agreement (the “Patent Transfer Agreement”), according to which the Subsidiary assigned to Entera all of its rights to a patent application related to the oral administration of proteins that it has licensed to Entera since August 2010, in return for royalties of 3% of Entera’s net revenues and a license back of that patent application for use in respect of diabetes and influenza. As of December 31, 2023, Entera had not paid any royalties to the Subsidiary. On December 11, 2018, Entera announced that it had entered into a research collaboration and license agreement with Amgen, Inc. (“Amgen”). To the extent that the license granted to Amgen results in net revenues as defined in the Patent Transfer Agreement, the Subsidiary will be entitled to the aforementioned royalties. As part of a consulting agreement with a third party dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011. b. According to the HTIT License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”). Pursuant to the HTIT License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%. The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory. The HTIT License Agreement shall remain in effect until the expiration of the royalty term. The License Agreement contains customary termination provisions. Among others, the Company’s involvement through the product submission date includes consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis. As of December 31, 2023, the Company has received milestone payments in an aggregate amount of $20,500 as follows: the initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019. On August 21, 2020, the Company received a letter from HTIT, disputing certain pending payment obligations of HTIT under the TLA. The payment obligation being disputed is $6,000, out of which only an amount of $2,000 has been received and has been included in deferred revenue in each of the consolidated balance sheets as of the years ended December 31, 2023, and December 31, 2022. The Company wholly disputed the claims made by HTIT and is planning to resolve any such claims as part of the Company’s discussions with HTIT. For the Company’s revenue recognition policy, see note 1m. On January 22, 2024, the Company and its wholly-owned subsidiary, Oramed Ltd., entered into a Joint Venture Agreement (the “JV Agreement”), with Hefei Tianhui Biotech Co., Ltd. (“HTIT Biotech”), and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech (“HTIT Sub,” and together with HTIT Biotech, “HTIT”), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties will establish a joint venture (the “JV”), based on the Company’s oral drug delivery technology. For further details, see note 14. c. On November 13, 2022, the Company entered the Medicox License Agreement with Medicox. The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. The Medicox License Agreement is for ten years, but the parties have the right to terminate it with a 180 days-notice. Medicox will comply with agreed distribution targets and will purchase ORMD-0801 at an agreed upon transfer price per capsule. In addition, Medicox will pay the Company up to $15,000 in developmental milestones, $2,000 of which were received by the Company in 2022, and up to 15% royalties on gross sales. Medicox will also be responsible for obtaining a regulatory approval in the Republic of Korea. For the Company’s revenue recognition policy, see note 1m. d. Grants from the Israel Innovation Authority (“IIA”) Under the terms of the Company’s funding from the IIA, royalties of 3% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on SOFR. At the time the grants were received, successful development of the related projects was not assured. The total amount that was received through December 31, 2023 was $2,208 ($2,559 including interest). All grants were received before the year ended August 31, 2020 and recorded as a reduction of research and development expenses at that time. As of December 31, 2023, the liability to the IIA was $59. The royalty expenses which are related to the funded project were recognized in cost of revenues in the relevant periods. e. Leases On August 2, 2020, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement is for a period of 60 months commencing September 1, 2020. The Subsidiary has the option to extend the period for another 60 months. The annual lease payment, including management fees, as of December 31, 2023 is approximately NIS 435 ($120). As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments. For accounting purposes, the lease period is 60 months. On December 2, 2021, the Subsidiary entered into an addendum (the “Addendum”) to the current lease agreement for its facilities in Israel. The Addendum refers to the lease of an additional space of 264 square meters for a period of 60 months commencing February 1, 2022. The Subsidiary has the option to extend the period for another 60 months. The annual lease payment, including management fees, is approximately NIS 435 ($120). As security for its obligation under the Addendum, the Company provided a bank guarantee in an amount equal to three monthly lease payments. For accounting purposes, the lease commenced on February 1, 2022 as the Subsidiary did not have access to the space until that date. For accounting purposes, the lease period is 60 months. The total expenses related to leases were $236 for the year ended December 31, 2023, and $264 for the year ended December 31, 2022. The right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate based on the information available at the date of determining the present value of the lease payments. The Company’s incremental borrowing rate is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located. The Company has various operating leases for office space and vehicles that expire through 2027. Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of December 31, 2023 and 2022: December 31, December 31, Operating right-of-use assets $ 694 $ 987 Operating lease liabilities, current 267 247 Operating lease liabilities long-term 342 647 Total operating lease liabilities $ 609 $ 894 Weighted Average of Remaining Lease Term Operating leases 2.5 3.41 Weighted Average Discount Rate Operating leases 3.15 % 3.15 % Operating cash flows from operating lease for the years ended December 31, 2023 and 2022 were $267 and $214, respectively. Lease payments for the Company’s right-of-use assets over the remaining lease periods as of December 31, 2023 are as follows: December 31, 2024 $ 282 2025 222 2026 120 2027 10 Total undiscounted lease payments 634 Less: Interest* (25 ) Present value of lease liabilities $ 609 * Future lease payments were discounted by 3%-5.75% interest rate. f. Legal expenses Following the Company’s 2019 annual meeting of stockholders, a complaint was filed in the Court of Chancery of the State of Delaware against the Company and the members of the Board of Directors. On April 27, 2022, the Court of Chancery of the State of Delaware approved the terms of a settlement between the Company and the plaintiff in the complaint, awarding the plaintiff an amount of $850 in attorneys’ fees, which was paid on April 28, 2022 and included in general and administrative expenses in the first quarter of 2022. All other details of the settlement were previously agreed by the parties and acted upon at the Company’s 2021 annual meeting of stockholders. g. Investment in Diasome Pharmaceuticals, Inc. On August 26, 2022, the Company entered into a stock purchase agreement with Diasome Pharmaceuticals, Inc. (“Diasome”) pursuant to which the Company purchased shares of Series B preferred stock of Diasome for an aggregate purchase price of approximately $2,700. Following the purchase, the Company holds less than 5% of the issued and outstanding stock of Diasome on a diluted basis. The stock purchase agreement provides the Company with the option to purchase additional preferred shares of stock on a pro rata basis at similar terms to the terms and conditions of the current round contingent upon Diasome achieving certain milestones. The Company accounts for the investment under the measurement alternative in ASC 321, whereby the equity investment is recorded at cost, less impairment. The carrying amount will be subsequently remeasured to its fair value in accordance with the provisions of ASC 820 when observable price changes occur as of the date the transaction occurred, or it is impaired. Any adjustments to the carrying amount are recorded in net income.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 - STOCKHOLDERS’ EQUITY: The following are the significant capital stock transactions that took place during the year ended December 31, 2023 and 2022: a. On July 15, 2021, the Company entered into a new equity distribution agreement (the “New Equity Distribution Agreement”) with Canaccord Genuity, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000 from time to time through Canaccord Genuity. The New Equity Distribution Agreement replaced the Equity Distribution Agreement, once it had been exhausted. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated July 15, 2021. The Company paid the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the New Equity Distribution Agreement. As of December 31, 2022, 273,997 shares were respectively issued under the New Equity Distribution Agreement for aggregate net proceeds of $5,129. b. On September 1, 2021, the Company entered into a controlled equity offering agreement (the “Cantor Equity Distribution Agreement”) with Cantor Fitzgerald & Co., as agent, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $100,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated July 26, 2021 and prospectus supplement dated September 1, 2021. The Company paid the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the Cantor Equity Distribution Agreement. As of December 31, 2023 and through March 6, 2024, 1,971,447 shares were issued under the Cantor Equity Distribution Agreement for aggregate net proceeds of $26,253. c. On November 3, 2021, the Company entered into a securities purchase agreement with several institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of 2,000,000 shares of the Company’s common stock to the Purchasers for an offering price of $25 per share. The closing of the sale of the shares occurred on November 5, 2021. The net proceeds to the Company from the Offering, after deducting the placement agent’s fees and expenses and the Company’s Offering expenses, were approximately $46,375. d. As of December 31, 2023, the Company had outstanding warrants exercisable starting February 25, 2020 for 20,000 shares of common stock at an exercise price of $4.13 per share and expiring on April 15, 2029. The following table presents the warrant activity for the years ended December 31, 2023 and 2022: Year ended December 31, 2023 2022 Warrants Weighted- Warrants Weighted- Warrants outstanding at beginning of year 150,705 $ 4.71 158,375 $ 4.78 Issued - $ - - $ - Exercised - $ - 4,200 $ 4.80 Expired 130,705 $ 4.80 3,470 $ 7.81 Warrants outstanding at end of year 20,000 $ 4.13 150,705 $ 4.71 Warrants exercisable at end of year 20,000 $ 4.13 150,705 $ 4.71

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 10 - STOCK-BASED COMPENSATION: The Company makes awards only under the 2019 Plan, under which, the Company had reserved a pool of 7,500,000 shares of the Company’s common stock which may be issued at the discretion of the Board of Directors from time to time. Under this 2019 Plan, each option or RSU is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options and RSUs is 10 years. The following are the significant stock options and RSUs transactions with employees, board members and non-employees made during the years ended December 31, 2023 and 2022: a. On January 3, 2022, the Company granted an aggregate of 150,000 shares of the Company’s common stock to its President and Chief Executive Officer. The total fair value of these shares on the date of grant was $2,084, using the quoted closing market share price of $13.89 on the Nasdaq Capital Market on the date of grant. b. On January 3, 2022, the Company granted an aggregate of 207,500 RSUs representing a right to receive shares of the Company’s common stock to the Company’s employees and members of the Board of Directors as follows: 63,000 to the President and Chief Executive Officer; 42,000 to the Chief Scientific Officer; 21,000 to the Chief Operating and Business Officer, 19,000 to the Chief Financial Officer and Treasurer, 19,000 to the Chief Commercial Officer, 18,000 to the Chief Legal Officer and Secretary (effective as of the time his employment with the Company commenced on January 9, 2022), an aggregate of 24,000 to four board members and 1,500 to an employee. The RSUs vest in four equal annual installments on each of January 1, 2023, 2024, 2025 and 2026. The total fair value of these RSUs on the date of grant was $2,849, using the quoted closing market share price of $13.89 on the Nasdaq Capital Market on the date of grant and $12.03 for the Chief Legal Officer’s grant (equivalent to the closing price of the Company’s common stock on January 10, 2022, which represents the first trading date after his employment with the Company commenced). c. On January 3, 2022, the Company granted options to purchase an aggregate of 321,500 shares of the Company’s common stock to the Company’s employees and board members at an exercise price of $13.89 per share (equivalent to the closing price of the Company’s common stock on the date of grant) as follows: 107,000 to the President and Chief Executive Officer; 72,000 to the Chief Scientific Officer; 36,000 to the Chief Operating and Business Officer, 32,000 to the Chief Financial Officer and Treasurer and 32,000 to the Chief Commercial Officer, an aggregate of 40,000 to four board members and 2,500 to an employee. The options vest in four equal annual installments on each of January 1, 2023, 2024, 2025 and 2026. As of December 31, 2023, 82,875 of such options are vested. These options expire on January 3, 2032. The total fair value of these options on the date of grant was $2,630, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $13.89; dividend yield of 0% for all years; expected volatility of 63.05%; risk-free interest rates of 1.46%; and expected term of 6.25 years. d. On January 3, 2022, the Company granted options to purchase an aggregate of 30,000 shares of the Company’s common stock to the Company’s Chief Legal Officer and Secretary (effective as of the time his employment with the Company commenced on January 9, 2022), at an exercise price of $12.03 per share (equivalent to the closing price of the Company’s common stock on January 10, 2022, which represents the first trading date after his employment with the Company commenced). The options vest in four equal annual installments on each of January 1, 2023, 2024, 2025 and 2026. As of December 31, 2022, none of such options are vested. These options expire on January 3, 2032. The total fair value of these options on the date of grant was $214, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $12.03; dividend yield of 0% for all years; expected volatility of 63.22%; risk-free interest rates of 1.60%; and expected term of 6.25 years. e. On May 2, 2022, the Company granted 4,500 RSUs representing a right to receive shares of the Company’s common stock to Mr. Yadin Rozov, a former member of the Company’s board of directors. The RSUs shall vest in four equal annual installments on each of May 2, 2023, 2024, 2025 and 2026. The total fair value of these RSUs on the date of grant was $23, using the quoted closing market share price of $5.14 on the Nasdaq Capital Market on the last trading day before the date of grant. f. On May 2, 2022, the Company granted options to purchase an aggregate of 7,500 shares of the Company’s common stock to Mr. Yadin Rozov, a former member of the Company’s board of directors, at an exercise price of $5.14 per share (equivalent to the closing price of the Company’s common stock on the last trading day before the date of grant). The options shall vest in four equal annual installments on each of May 2, 2023, 2024, 2025 and 2026. As of December 31, 2022, none of such options are vested. These options expire on May 2, 2032. The total fair value of these options on the date of grant was $24, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $5.14; dividend yield of 0% for all years; expected volatility of 65.26%; risk-free interest rates of 3.03% and expected term of 6.26 years. g. On July 28, 2022, the Company granted an aggregate of 404,100 RSUs representing a right to receive shares of the Company’s common stock to the Company’s executive officers, employees and board members. The RSUs granted to certain employees, executive officers and board members shall vest in three equal annual installments on each of January 1, 2024, 2025 and 2026 and the RSUs granted to certain employees will vest in three equal annual installments on each of January 1, 2023, 2024 and 2025. The total fair value of these RSUs on the date of grant was $3,423, using the quoted closing market share price of $8.47 on the Nasdaq Capital Market on the date of grant. h. On July 28, 2022, the Company granted 34,000 shares of the Company’s common stock to each of the Company’s President and Chief Executive Officer and Chief Scientific Officer. These shares vested in full on August 1, 2022. The total fair value of these shares on the date of grant was $576, using the quoted closing market share price of $8.47 on the Nasdaq Capital Market on the date of grant. i. On July 28, 2022, the Company granted an aggregate of 175,500 performance based RSUs (“PSUs”) representing a right to receive shares of the Company’s common stock to the Company’s executive officers. The PSUs were to vest in two installments upon achievement of the following milestones: (i) two thirds were to vest upon receipt of positive topline data in the first oral insulin Phase 3 clinical trial; and (ii) one third was to vest upon completion of enrollment of the second oral insulin Phase 3 clinical trial by June 30, 2023. Following the results of the ORA-D-013-1 Phase 3 trial and the termination of the ORA-D-013-2 Phase 3 trial, these performance goals have not been met and the PSUs did not vest. The total fair value of these PSUs on the date of grant was $1,486, using the quoted closing market share price of $8.47 on the Nasdaq Capital Market on the date of grant. j. On September 18, 2022, Oravax granted options to purchase an aggregate of 328,318 shares of Oravax’s common stock to employees and board members of Oravax and to other service providers at an exercise price of $3.91 per share. The options will vest in four annual installments as follows: the first installment vested immediately on the grant date and the remaining three installments shall vest on each of December 31, 2022, 2023 and 2024. These options expire on September 18, 2032. The total fair value of these options on the date of grant was $665, using the Black Scholes option pricing model and was based on the following assumptions: stock price of $3.91; dividend yield of 0% for all years; expected volatility of 52.87%; risk-free interest rates of 3.62%; and expected term of 5.49 years. k. On April 17, 2023, the Company granted an aggregate of 868,500 RSUs representing a right to receive shares of the Company’s common stock to executive officers and board members of the Company. The RSUs will vest in twelve equal quarterly installments starting May 1, 2023. The total fair value of these RSUs on the date of grant was $1,980, using the quoted closing market share price of $2.28 on the Nasdaq Capital Market on the date of grant. l. On April 17, 2023, the Company granted an aggregate of 245,500 performance based RSUs (“PSUs”) representing a right to receive shares of the Company’s common stock to executive officers of the Company. The PSUs vested on May 26, 2023, upon the Company’s common stock achieving and maintaining a specified price per share. The total fair value of these PSUs on the date of grant was $550, using the Monte-Carlo model. m. On May 1, 2023, the Company granted an aggregate of 20,000 RSUs representing a right to receive shares of the Company’s common stock to a new board member. The RSUs will vest in twelve quarterly installments starting May 1, 2023. The total fair value of these RSUs on the date of grant was $49, using the quoted closing market share price of $2.45 on the Nasdaq Capital Market on the date of grant. n. During 2023, 132,000 stock options and 110,917 unvested RSUs were forfeited, due to termination of the employment of an executive officer, resulting in a reversal of $663 in sales and marketing expenses. o. Options to employees, directors and non-employees The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model or Monte Carlo model with the following range of assumptions: For options granted 2023 2022 Expected option life (years) - 6.25-6.26 Expected stock price volatility (%) - 63.05-65.26 Risk free interest rate (%) - 1.46-3.03 Expected dividend yield (%) - 0.0 A summary of the status of the stock options granted to employees and directors as of December 31, 2023 and 2022 and changes during the year ended on those dates, is presented below: Year ended December 31, 2023 2022 Number Weighted Number Weighted $ $ Options outstanding at beginning of year 2,041,676 8.47 1,942,117 7.14 Changes during the year: Granted - - 359,000 13.55 Forfeited (132,000 ) 14.81 (48,334 ) 10.59 Expired - - (144,000 ) 4.08 Exercised - - (67,107 ) 5.03 Options outstanding at end of year 1,909,676 8.03 2,041,676 8.47 Options exercisable at end of year 1,479,426 7.15 1,261,426 6.86 Weighted average fair value of options granted during the year $ - $ 7.99 Expenses recognized in respect of stock options granted to employees and directors, for the years ended December 31, 2023 and 2022, were $811 and $2,662, respectively. No options were granted during the year ended December 31, 2023. The total intrinsic value of employees’ options exercised during the year ended December 31, 2022 was $243. The following table presents summary information concerning the options granted to employees and directors outstanding as of December 31, 2023: Exercise Number outstanding Weighted Weighted $ Years $ 1-6 857,250 5.85 3.94 6.23-9.12 283,008 3.80 7.96 10.40-20.19 769,418 6.52 12.62 1,909,676 5.82 8.03 1,479,426 options granted to employees and directors were outstanding and exercisable as of December 31, 2023, compared to 1,261,426 as of December 31, 2022. As of December 31, 2023, there were $707 of unrecognized compensation costs related to non-vested options previously granted to employees and directors. The unrecognized compensation costs are expected to be recognized over a weighted average period of 0.8 years. A summary of the status of the stock options granted to non-employees outstanding as of December 31, 2023 and 2022, and changes during the years ended December 31, 2023 and 2022, is presented below: Year ended 2023 2022 Number Weighted Number Weighted $ $ Options outstanding at beginning of year 47,000 4.31 51,500 4.26 Changes during the year: Granted - - - - Exercised - - (4,500 ) 3.74 Forfeited - - - - Expired - - - - Options outstanding at end of year 47,000 4.31 47,000 4.31 Options exercisable at end of year 47,000 4.31 47,000 4.31 Weighted average fair value of options granted during the year $ - $ - The Company recorded no stock-based compensation related to non-employees’ awards during the years ended December 31, 2023 and 2022. During the year ended December 31, 2023, no options were exercised. During the year ended December 31, 2022, 4,500 options were exercised by non-employees for a total intrinsic value of $24. The following table presents summary information concerning the options granted to non-employees outstanding as of December 31, 2023: Range of Number outstanding Weighted Weighted 3.74-5.08 47,000 5.98 4.31 47,000 options granted to non-employees were outstanding and exercisable as of December 31, 2023. As of December 31, 2023, there were no unrecognized compensation costs related to non-vested options previously granted to non-employees. p. Restricted stock units The following table summarizes the activities for unvested RSUs granted to employees and directors for the years ended December 31, 2023 and 2022: Year ended 2023 2022 Number of RSUs Outstanding at the beginning of period 1,561,570 801,303 Granted 1,134,000 1,009,600 Issued (574,791 ) (217,333 ) Forfeited (286,417 ) (32,000 ) Outstanding at the end of the period 1,834,362 1,561,570 Vested during the period 521,625 218,000 Vested and unissued at period end 212,136 265,302 The Company recorded compensation expenses related to RSUs of $3,210 for the year ended December 31, 2023 and $8,365 for the year ended December 31, 2022. As of December 31, 2023, there were unrecognized compensation costs of $2,693 related to RSUs. The unrecognized compensation costs are expected to be recognized over a weighted average period of 1 year. The following table summarizes the activities for unvested RSUs granted to non-employees for the years ended December 31, 2023 and 2022: Year ended 2023 2022 Number of RSUs Outstanding at the beginning of period 4,000 8,000 Granted - - Issued (4,000 ) (4,000 ) Forfeited - - Outstanding at the end of the period - 4,000 Vested during the period 4,000 4,000 Vested and unissued at period end - - The Company recorded compensation expenses related to RSUs of $26 for the year ended December 31, 2023, compared to $92 compensation expenses recorded for the year ended December 31, 2022. As of December 31, 2023, there were no unrecognized compensation costs related to RSUs.

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Dec. 31, 2023
Financial Income and Expenses[Abstract]
FINANCIAL INCOME AND EXPENSES	NOTE 11 - FINANCIAL INCOME AND EXPENSES: a. Financial income Year ended 2023 2022 Income from interest on the Senior DIP Loan Agreement and deposits $ 8,016 $ 3,473 Exchange rate differences, net - 176 Income from interest on corporate bonds 10 100 Revaluation of securities, net 16,461 - Other 143 5 $ 24,630 $ 3,754 b. Financial expenses Year ended 2023 2022 Exchange rate differences, net $ 124 $ - Bank and broker commissions 29 14 Loss from securities, net - 43 Revaluation of securities, net 69 763 Fees regarding Scilex transaction 1,514 - Interest expenses 2,037 - $ 3,773 $ 820

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2023
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 12 - TAXES ON INCOME: Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Israeli subsidiary. a. Corporate taxation in the U.S. The applicable corporate tax rate for the Company is 21%. As of December 31, 2023, the Company and Oravax Medical Inc. had an accumulated tax loss carryforward of approximately $28,000 (as of December 31, 2022, $24,000). Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January 1, 2018, have no expiration date, but they are limited to 80% of the company’s taxable income in any given tax year. Carryforward tax losses originating in tax years beginning prior to January 1, 2018, expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carryforward will expire in the years 2026 through 2037. b. Corporate taxation in Israel The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2023 and 2022 is 23%. As of December 31, 2023, the Subsidiary and Oravax Medical Ltd. had an accumulated tax loss carryforward of approximately $102,000 (as of December 31, 2022, approximately $87,000). Under the Israeli tax laws, carryforward tax losses have no expiration date. c. Deferred income taxes December 31, 2023 2022 In respect of: Net operating loss carryforward $ 27,757 $ 27,610 Research and development expenses 2,731 5,195 Revaluation of investments (2,611 ) - Other temporary differences 596 - Less - valuation allowance (28,473 ) (32,805 ) Net deferred tax assets $ - $ - Deferred taxes are determined based on temporary differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance. d. Income (Loss) before taxes on income and income taxes included in the income statements of operations Year ended 2023 2022 Income (loss) before taxes on income: U.S. $ 11,604 $ (11,164 ) Outside U.S. (6,516 ) (26,500 ) $ 5,088 $ (37,664 ) Taxes on income (tax benefit): Current: U.S. - - Outside U.S. - (100 ) $ - $ (100 ) e. Reconciliation of the statutory tax benefit to effective tax expense Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense: Year ended 2023 2022 Income (loss) before income taxes as reported in the consolidated statement of comprehensive loss $ 5,088 $ (37,664 ) Statutory tax (benefit) expense – 21% 1,068 (7,909 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax (4,332 ) 7,290 Disallowable deductions 731 1,152 Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd. (305 ) (533 ) Prior year true-up 2,838 - Withholding tax, see note 12d above - 100 Uncertain tax position - - Taxes on income for the reported year $ - $ 100 f. Uncertainty in Income Taxes ASC 740, “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. The following table summarizes the activity of the Company unrecognized tax benefits: Year ended 2023 2022 Balance at Beginning of Year $ 11 $ 11 Decrease in uncertain tax positions for the current year - - Balance at End of Year $ 11 $ 11 The Company does not expect unrecognized tax expenses to change significantly over the next 12 months. The Company is subject to U.S. Federal income tax examinations for the tax years of 2020 through 2022. The Subsidiary is subject to Israeli income tax examinations for the tax years of 2017 through 2022. g. Valuation Allowance Rollforward Period ended Balance at Additions Balance at Allowance in respect of carryforward tax losses: Year ended December 31, 2023 $ 32,805 $ (4,332 ) $ 28,473 Year ended December 31, 2022 26,659 6,146 32,805

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13 - RELATED PARTY TRANSACTIONS: a. On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the Chief Scientific Officer, whereby the President and Chief Executive Officer and the Chief Scientific Officer, through KNRY, provide services to the Company (the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 140 days, prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the President and Chief Executive Officer and the Chief Scientific Officer is NIS 146,705 ($40) and 106,400 ($29), respectively. In addition to the Consulting Agreements, based on a relocation cost analysis, the Company paid for certain direct costs, related taxes and expenses incurred in connection with the relocation of the President and Chief Executive Officer to New York. During the ten month period ended October 31, 2022, such relocation expenses totaled $331. Following the relocation of the President and Chief Executive Officer to the State of Israel, the Company entered into two agreements with the President and Chief Executive Officer, replacing his above-mentioned consulting agreement through KNRY, substantially on the same terms, in order to allocate his time and services between the Company and the Subsidiary. Effective November 1, 2022, the Company entered into a consulting agreement with Shnida Ltd. (“Shnida”), whereby the President and Chief Executive Officer, through Shnida, provides services as President and Chief Executive Officer of the Company. The agreement is terminable by either party upon 140 days prior written notice. The agreement provides that Shnida will be reimbursed for reasonable expenses incurred in connection with performance of the agreement. Effective as of January 1, 2024, the President and Chief Executive Officer receives a monthly consulting fee of NIS 96,825 ($27), plus value added tax. Pursuant to the agreement, Shnida and the President and Chief Executive Officer each agree that during the term of the agreement and for a 12-month period thereafter, none of them will compete with the Company nor solicit employees of the Company. In addition, the Company, through the Subsidiary, has entered into an employment agreement with the President and Chief Executive Officer, effective as of November 1, 2022, pursuant to which, effective as of January 1, 2024, the President and Chief Executive Officer receives gross monthly salary of NIS 51,591 ($14) in consideration for his services as President and Chief Executive Officer of the Subsidiary. In addition, the President and Chief Executive Officer is provided with a phone and a company car pursuant to the terms of his agreement. b. Balances with related parties: December 31, 2023 2022 Accounts payable and accrued expenses - Shnida $ 160 $ - Accounts payable and accrued expenses - KNRY $ 165 $ 1 c. Expenses to related parties: Year ended 2023 2022 KNRY $ 486 $ 800 Shnida 445 146 Nadav Kidron (President and Chief Executive Officer) $ 296 $ 674

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 - SUBSEQUENT EVENTS: 1. On January 4, 2024, the Company granted an aggregate of 150,000 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to the board members will vest in three equal annual installments on each of January 1, 2025, 2026 and 2027. The total fair value of these RSUs on the date of grant was $359, using the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant. 2. On January 4, 2024, the Company granted an aggregate of 37,610 RSUs representing a right to receive shares of the Company’s common stock to the Company’s board members. The RSUs granted to certain board members will vest in four quarterly installments on each of April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The total fair value of these RSUs on the date of grant was $90, using the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant. 3. On January 4, 2024, the Company granted an aggregate of 950,500 RSUs representing a right to receive shares of the Company’s common stock to the Company’s executive officers and one employee. The RSUs granted to executive officers and one employee will vest in twelve equal quarterly installments starting January 8, 2024. The total fair value of these RSUs on the date of grant was $2,272, using the quoted closing market share price of $2.39 on the Nasdaq Capital Market on the date of grant. 4. On January 4, 2024, the Company granted an aggregate of 294,000 PSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The PSUs shall vest upon the Company’s common stock achieving and maintaining a specified price per share. The total fair value of these PSUs on the date of grant was $691, using the Monte-Carlo model. 5. On January 22, 2024, the Company and its wholly-owned subsidiary, Oramed Ltd., entered into the JV Agreement, with HTIT Biotech and HTIT Sub, pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties will establish a JV, based on the Company’s oral drug delivery technology. The JV will focus on the development and worldwide commercialization of innovative products based on the Company’s oral insulin and POD™ (Protein Oral Delivery) pipeline and HTIT’s manufacturing capabilities and technologies. The parties intend for the JV to use the protocol the Company is currently working on to initiate a Phase 3 oral insulin trial in the United States. The Company and HTIT will initially hold equal shares in the JV, with each owning 50% of the equity. The Board of Directors will initially consist of equal representation from HTIT and the Company. HTIT will contribute to the JV $70,000 in cash, while the Company will contribute $20,000 (comprised of $10,000 in cash and $10,000 in shares of the Company’s common stock that will be subject to certain registration rights) and will transfer intellectual property related to its oral insulin and POD™ technology, as well as other assets in the Company’s pipeline. HTIT will have an option to invest additional funds into the JV up to an aggregate amount of $20,000, thereby increasing its equity holdings and board representation. The Company will be entitled to receive a 3% royalty on gross revenues of the JV generated from Company-related assets. The consummation of the JV Agreement is subject to and contingent upon the parties entering into additional agreements within a three-month period, including an asset transfer agreement for the transfer of the Company’s intellectual property to the JV, a commercial supply agreement for the manufacture and supply of products by HTIT to the JV, as well as other documents and agreements to regulate the relationship of the parties and the JV to be formed pursuant to the JV Agreement. There is no assurance that the parties will complete and sign these additional agreements within the agreed timeline or at all. If such agreements are not signed within the agreed timeframe, then either party may apply a 30-day extension, after which the JV Agreement may be terminated and voided by either party. Thereafter, the consummation of the JV transaction is further subject to the satisfaction or waiver of certain other closing conditions within a three-month period following the completion of the aforesaid ancillary agreements. If the closing conditions are not met within the agreed timeframe, then either party may apply a 30-day extension, after which the JV Agreement may be terminated and voided by either party. In addition, completion of the transactions contemplated under the JV Agreement is subject to the satisfaction or waiver of customary and certain other closing conditions. 6. On January 30, 2024, the Company granted an aggregate of 3,750 RSUs representing a right to receive shares of the Company’s common stock to one of the Company’s board members. The RSUs granted to the board member will vest in four quarterly installments on each of April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The total fair value of these RSUs on the date of grant was $11, using the quoted closing market share price of $2.98 on the Nasdaq Capital Market on the date of grant.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 5,525	$ (36,561)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2023 shares	Dec. 31, 2023 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Mr. David Silberman [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On January 8, 2024, Mr. David Silberman, our Chief Financial Officer, terminated a trading plan before expiration that was previously entered into to satisfy the affirmative defense of Rule 10b5–1(c) under the Exchange Act. This plan was entered into on June 25, 2023 and was meant to expire upon the earlier of May 15, 2024 or when 128,625 of Oramed’s shares of common stock were sold, which was the aggregate maximum number of shares to be sold under the plan.
Name	Mr. David Silberman
Title	Chief Financial Officer
Rule 10b5-1 Arrangement Terminated	false
Termination Date	January 8, 2024
Aggregate Available	128,625	128,625
Mr. Joshua Hexter [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On January 8, 2024, Mr. Joshua Hexter, our Chief Operating and Business Officer, terminated a trading plan before expiration that was previously entered into to satisfy the affirmative defense of Rule 10b5–1(c) under the Exchange Act. This plan was entered into on June 28, 2023 and was meant to expire upon the earlier of June 27, 2025 or when 245,333 of Oramed’s shares of common stock were sold, which was the aggregate maximum number of shares to be sold under the plan.
Name	Mr. Joshua Hexter
Title	Chief Operating and Business Officer
Rule 10b5-1 Arrangement Terminated	false
Termination Date	January 8, 2024
Aggregate Available	245,333	245,333
Mr. Netanel Derovan [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On February 6, 2024, Mr. Netanel Derovan, our former Chief Legal Officer, terminated a trading plan before expiration that was previously entered into to satisfy the affirmative defense of Rule 10b5–1(c) under the Exchange Act. This plan was entered into on June 8, 2023 and was meant to expire upon the earlier of June 28, 2024 or when 88,250 of Oramed’s shares of common stock were sold, which was the aggregate maximum number of shares to be sold under the plan.
Name	Mr. Netanel Derovan
Title	Chief Legal Officer
Rule 10b5-1 Arrangement Terminated	false
Termination Date	February 6, 2024
Aggregate Available	88,250	88,250

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
General	a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company,” unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. On July 30, 2019, the Subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited (the “Hong Kong Subsidiary”). As of December 31, 2023, the Hong Kong Subsidiary has no operations. On March 18, 2021, the Company entered into a license agreement (the “Oravax License Agreement”) with Oravax Medical Inc. (“Oravax”) and into a stockholders agreement (the “Stockholders Agreement”) with Akers Biosciences Inc., Premas Biotech Pvt. Ltd., Cutter Mill Capital LLC (“Cutter Mill”) and Run Ridge LLC (“Run Ridge”). According to the Stockholders Agreement, Oravax issued 1,890,000 shares of its capital stock to the Company, representing 63% of the issued and outstanding share capital of Oravax, on a fully diluted basis, as of the date of issuance. Consequently, Oramed consolidates Oravax in its consolidated financial statements since that time. On November 23, 2021, Oravax incorporated a wholly-owned subsidiary in Israel, Oravax Medical Ltd., which is engaged in research and development. Effective January 1, 2022, Oravax transferred its rights and obligations under the Oravax License Agreement to Oravax Medical Ltd. On January 11, 2023, the Company announced that the ORA-D-013-1 Phase 3 trial did not meet its primary or secondary endpoints. As a result, the Company terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial. As these results are considered a triggering event, the Company evaluated all of its long lived assets which include fixed assets and operating lease right-of-use assets in the first quarter of 2023 and concluded that no impairment was required. In 2023, the Company completed an analysis of the data from the ORA-D-013-1 Phase 3 trial and found that subpopulations of patients with pooled specific parameters, such as body mass index (BMI), baseline HbA1c and age, responded well to oral insulin. These subsets exhibited an over 1% placebo adjusted, statistically significant, reduction in HbA1c. Based on this analysis, the Company is working on a protocol for a new Phase 3 clinical trial to be submitted to the U.S. Food and Drug Administration (the “FDA”). Concurrently, the Company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for the Company’s stockholders. 2) Development and liquidity risks The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Following the termination of the ORA-D-013-1 and ORA-D-013-2 Phase 3 trials, the Company’s research and development activities have been significantly reduced while it conducted a strategic review process. As a result, the Company is currently incurring lower research and development and sales and marketing expenses. The Company is working on a protocol for a new Phase 3 clinical trial to be submitted to the FDA. Concurrently, the Company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities. Based on the Company’s current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that the Company will not need additional funds prior to such time. If there are unexpected increases in its operating expenses, the Company may need to seek additional financing during the next 12 months. The Company may also need additional funds to realize the decisions made as part of its strategic review process. The Company cannot predict the outcome of these activities. On August 7, 2023, the Company entered into a Stock Purchase Agreement, as subsequently amended on August 9, 2023 and August 21, 2023, (the “Sorrento SPA”), with Sorrento Therapeutics, Inc. (“Sorrento”), to acquire certain equity securities of Scilex Holding Company (“Scilex”), owned by Sorrento (the “Purchased Securities”), for a purchase price of $105,000. Sorrento and its affiliated debtor, Scintilla Pharmaceuticals, Inc. (“Scintilla” and together with Sorrento, the “Debtors”) are in Chapter 11 bankruptcy proceedings. On August 9, 2023, the Company entered into a Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement (the “Senior DIP Loan Agreement”) with the Debtors in the principal amount of $100,000, which included a non-refundable closing fee of $450 paid in full out of the proceeds. This amount was subsequently drawn in full by the Debtors and was intended to be used by the Company as a credit for the consideration for the Purchased Securities, with an additional $5,000 in cash to be paid by the Company at closing. Thereafter, the Company and Sorrento continued discussions and negotiations relating to the sale contemplated under the Sorrento SPA. On September 21, 2023, the Company entered into and consummated the transactions contemplated by a Securities Purchase Agreement (the “Scilex SPA”) with Scilex and Acquiom Agency Services LLC. Pursuant to the Scilex SPA, in exchange for Scilex assuming outstanding obligations of Sorrento under the Senior DIP Loan Agreement (the “DIP Assumption”) and for the ability to credit the amounts assumed under the DIP Assumption in exchange for certain equity securities of Scilex owned by Sorrento, Scilex (i) issued to the Company (A) a Senior Secured Promissory Note due 18 months from the date of issuance in the principal amount of $101,875 (the “Note”), which includes accrued and unpaid interest of $875 under the Senior DIP Loan Agreement and $1,000 of fees added to the principal amount of the Note, (B) the Closing Penny Warrant (as defined herein), and (C) the Subsequent Penny Warrants (as defined herein), and (ii) caused the Transferred Warrants (as defined herein) to be transferred to the Company. For further details, see note 4. On August 8, 2023, the Company borrowed an aggregate of $99,550 pursuant to loan agreements from Israel Discount Bank Ltd. For further details, see note 7.
Basis of presentation	b. Basis of presentation The consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Use of estimates in the preparation of financial statements	c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation and to the investments at fair value (for further details, see note 4).
Functional currency	d. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
Principles of consolidation	e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.
Cash equivalents	f. Cash equivalents The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Fair value measurement	g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: December 31, 2023 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 297 - - 297 Entera 70 - - 70 Transferred Warrants (see note 4) 1,440 - - 1,440 Closing Penny Warrant (see note 4) - 9,180 - 9,180 Subsequent Penny Warrants (see note 4) - - 6,502 6,502 The Note (see note 4) - - 93,066 93,066 $ 1,807 $ 9,180 $ 99,568 $ 110,555 December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 352 - - 352 Entera 85 - - 85 $ 437 $ - $ - $ 437 The fair value of the investment in non-marketable equity securities as presented in note 5 was based on a Level 3 measurement. As of December 31, 2023, the carrying amounts of cash equivalents, short-term deposits, Short-Term Borrowings (as defined in note 7) and accounts payable approximate their fair values due to the short-term maturities of these instruments. As of December 31, 2022, the carrying amounts of cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities of these instruments. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.
Marketable securities	h. Marketable securities 1. Equity securities The Company measured the securities (investments in equity securities of DNA GROUP (T.R.) Ltd. (“DNA”), Entera Bio Ltd. (“Entera”) and the Transferred Warrants) at fair value, with changes in fair value recognized in earnings. 2. Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity.
Other non-marketable equity securities	i. Other non-marketable equity securities The Company also invested in non-marketable equity securities, through an investment in a privately held company. This equity investment does not have a readily determinable fair value. The investment is measured under the measurement alternative in Accounting Standards Codification (“ASC”) 321 “Investments – Equity Securities” to the extent such an investment is not subject to consolidation or the equity method. Under the measurement alternative, this equity investment is carried at cost, less any impairment, adjusted for changes resulting from observable price changes in transactions for an identical or similar investment of the same issuer. The investment would be impaired in accordance with the provisions of ASC 820 “Fair Value Measurement” if, based on a qualitative assessment of impairment indicators, the fair value of the investment is less than its carrying amount. If considered impaired, the difference between the carrying amount and fair value would be recorded in the consolidated statement of operations. For further details, see note 5.
Investments, at fair value	j. Investments, at fair value The Company invested in the Note and received Penny Warrants issued by Scilex (see note 4), for which it has elected the fair value option. Under the Fair Value Option Subsections of ASC Subtopic 825-10, Financial Instruments – Overall, the Company has the irrevocable option to report financial assets at fair value on an instrument-by-instrument basis. Changes in fair value are recorded under financial income, net and include interest income on the Note. Alongside the Note and the Penny Warrants, Scilex issued to the Company the Transferred Warrants. The Transferred Warrants meet the definition of a derivative under ASC 815 “Derivatives and Hedging,” and therefore will also be measured at fair value. Changes in the fair value of the Warrants are recorded under financial income, net.
Concentration of credit risks	k. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits, which are deposited in major financial institutions, marketable securities, and the Note (as defined herein). The Company is of the opinion that the credit risk in respect of these balances is remote, except for the Note (as defined herein) for which the credit risk is reflected in its fair value measurement (for further details, see note 4).
Income taxes	l. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 12. Taxes that would apply in the event of disposal of investments in the Israeli subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within 12 months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
Revenue recognition	m. Revenue recognition HTIT On November 30, 2015, the Company entered into a Technology License Agreement, with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”). As of December 31, 2023, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through December 31, 2023, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, of which $1,340 was recognized in the twelve month period ended December 31, 2023, and deferred the remaining amount of $2,000, which is presented as long-term deferred revenues on the consolidated balance sheet. Medicox On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 8c. Under ASC 606 “Revenue from Contracts with Customers,” the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer. The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts. The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company during the year ended December 31, 2022 and is currently presented under long-term deferred revenues. It also contains variable consideration of contractual milestone payments and sales-based royalties. The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of December 31, 2023, this support has not commenced, and no revenue was recognized from the Medicox License Agreement. If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage, going forward. The Company notes that its Phase 3 trial did not meet its primary or secondary endpoints (see note 1a.1). If Medicox chooses to terminate the agreement as a result of the outcome of the Phase 3 trials, the Company will accelerate revenue recognition and recognize it at such time.
Research and development	n. Research and development Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Clinical Research Organizations (“CROs”), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.
Stock-based compensation	o. Stock-based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options and restricted stock units (“RSUs”) with an exercise price using the Black Scholes pricing model, for stock options and RSUs with market conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees’ exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense is not reversed if the market conditions are not satisfied. The Company elects to account for forfeitures as they occur.
Earnings (loss) per common share	p. Earnings (loss) per common share Basic net earnings (loss) per common share are computed by dividing the net earnings (loss) attributable to stockholders for the period by the weighted average number of shares of common stock outstanding for each period, including vested RSUs. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for the year ended December 31, 2022. For the diluted earnings per share calculation for the year ended December 31, 2023, the weighted average number of shares outstanding during the year is adjusted for the potential dilution that could occur in connection with employee share-based payment, using the treasury stock method. The weighted average number of stock options, warrants, and RSUs that has been excluded from the calculation of the diluted income per share as of December 31, 2023 was 1,227,506 shares. The weighted average number of stock options, warrants and RSUs excluded from the calculation of diluted net loss was 3,356,203 for the year ended December 31, 2022.
Leases	q. Leases The Company leases real estate and cars for use in its operations, which are classified as operating leases. In addition to rent, the leases may require the Company to pay directly for fees, insurance, maintenance and other operating expenses. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right of use assets and operating lease liabilities in the consolidated balance sheets. Right of use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. Lease expenses are recognized on a straight-line basis over the lease term. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities but recognizes lease expenses over the lease term on a straight line basis. The Company also elected the practical expedient to not separate lease and non-lease components for all of its leases. Lease terms will include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company’s lease agreements have remaining lease terms ranging from 1 year to 4 years. Some of these agreements include options to extend the leases for up to an additional 5 years and some include options to terminate the leases immediately. See also note 8e.
New accounting pronouncements	r. New accounting pronouncements Recently adopted accounting pronouncements In June 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) “Financial Instruments—Credit Losses—Measurement of Credit Losses on Financial Instruments.” This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning after December 15, 2022, including interim periods within that year. The Company adopted the provisions of this update as of January 1, 2023, with no material impact on its consolidated financial statements. Recently issued accounting pronouncements, not yet adopted In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures.” This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280 “Segment Reporting”. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Schedule of Fair Value Measurement	The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: December 31, 2023 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 297 - - 297 Entera 70 - - 70 Transferred Warrants (see note 4) 1,440 - - 1,440 Closing Penny Warrant (see note 4) - 9,180 - 9,180 Subsequent Penny Warrants (see note 4) - - 6,502 6,502 The Note (see note 4) - - 93,066 93,066 $ 1,807 $ 9,180 $ 99,568 $ 110,555 December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets: Marketable Securities DNA 352 - - 352 Entera 85 - - 85 $ 437 $ - $ - $ 437

Short-Term Deposits (Tables)

Short-Term Deposits (Tables)	12 Months Ended
	Dec. 31, 2023
Short-Term Deposits [Abstract]
Schedule of Short Term Deposits	Composition December 31, 2023 2022 Annual Amount Annual Amount Dollar deposits 6.35-6.81 % $ 95,279 0.93-6.81 % $ 111,513

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2023
Marketable Securities [Abstract]
Schedule of Marketable Securities also Included Held to Maturity Securities	As of December 31, 2022, marketable securities also included held to maturity securities. December 31, 2023 2022 Short-term: DNA (see b below) $ - $ 352 Entera (see c below) - 85 Held to maturity securities (see d below) - 3,306 $ - $ 3,743 Long-term: DNA (see b below) $ 297 $ - Entera (see c below) 70 - Transferred Warrants (see note 4) 1,440 - $ 1,807 $ -
Schedule of Amortized Cost and Estimated Fair Value of Held-to-Maturity Securities	The amortized cost and estimated fair value of held-to-maturity securities as of December 31, 2022, are as follows: December 31, 2022 Amortized Gross Estimated Average Short-term: Commercial bonds $ 3,258 $ (82 ) $ 3,176 1.07 % Accrued interest 48 - 48 $ 3,306 $ (82 ) $ 3,224

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Composition: December 31, 2023 2022 Accounts payable $ 551 $ 2,175 Payroll and related accruals 453 529 Institutions - 11 Accrued liabilities 605 1,443 $ 1,609 $ 4,158

Short-Term Borrowings (Tables)

Short-Term Borrowings (Tables)	12 Months Ended
	Dec. 31, 2023
Short-Term Borrowings [Abstract]
Schedule of the Aggregate Remaining Annual Principal Payments on Debt Until Maturity	The aggregate remaining annual principal payments on debt until maturity are as follows: Annual 2024 49,550 Total $ 49,550

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments [Abstract]
Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities	The Company has various operating leases for office space and vehicles that expire through 2027. Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of December 31, 2023 and 2022: December 31, December 31, Operating right-of-use assets $ 694 $ 987 Operating lease liabilities, current 267 247 Operating lease liabilities long-term 342 647 Total operating lease liabilities $ 609 $ 894 Weighted Average of Remaining Lease Term Operating leases 2.5 3.41 Weighted Average Discount Rate Operating leases 3.15 % 3.15 %
Schedule of Right-of-Use Assets Over the Remaining Lease	Lease payments for the Company’s right-of-use assets over the remaining lease periods as of December 31, 2023 are as follows: December 31, 2024 $ 282 2025 222 2026 120 2027 10 Total undiscounted lease payments 634 Less: Interest* (25 ) Present value of lease liabilities $ 609 * Future lease payments were discounted by 3%-5.75% interest rate.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of Warrant Activity	The following table presents the warrant activity for the years ended December 31, 2023 and 2022: Year ended December 31, 2023 2022 Warrants Weighted- Warrants Weighted- Warrants outstanding at beginning of year 150,705 $ 4.71 158,375 $ 4.78 Issued - $ - - $ - Exercised - $ - 4,200 $ 4.80 Expired 130,705 $ 4.80 3,470 $ 7.81 Warrants outstanding at end of year 20,000 $ 4.13 150,705 $ 4.71 Warrants exercisable at end of year 20,000 $ 4.13 150,705 $ 4.71

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Stock-Based Compensation [Abstract]
Schedule of Fair Value Each Option Grant is Estimated	The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model or Monte Carlo model with the following range of assumptions: For options granted 2023 2022 Expected option life (years) - 6.25-6.26 Expected stock price volatility (%) - 63.05-65.26 Risk free interest rate (%) - 1.46-3.03 Expected dividend yield (%) - 0.0
Schedule of Activities for Unvested RSUs Granted to Employees and Directors	A summary of the status of the stock options granted to employees and directors as of December 31, 2023 and 2022 and changes during the year ended on those dates, is presented below: Year ended December 31, 2023 2022 Number Weighted Number Weighted $ $ Options outstanding at beginning of year 2,041,676 8.47 1,942,117 7.14 Changes during the year: Granted - - 359,000 13.55 Forfeited (132,000 ) 14.81 (48,334 ) 10.59 Expired - - (144,000 ) 4.08 Exercised - - (67,107 ) 5.03 Options outstanding at end of year 1,909,676 8.03 2,041,676 8.47 Options exercisable at end of year 1,479,426 7.15 1,261,426 6.86 Weighted average fair value of options granted during the year $ - $ 7.99
Schedule of Concerning the Options Granted to Non Employees Outstanding	The following table presents summary information concerning the options granted to employees and directors outstanding as of December 31, 2023: Exercise Number outstanding Weighted Weighted $ Years $ 1-6 857,250 5.85 3.94 6.23-9.12 283,008 3.80 7.96 10.40-20.19 769,418 6.52 12.62 1,909,676 5.82 8.03
Schedule of Stock Options Granted to Non Employees Outstanding	A summary of the status of the stock options granted to non-employees outstanding as of December 31, 2023 and 2022, and changes during the years ended December 31, 2023 and 2022, is presented below: Year ended 2023 2022 Number Weighted Number Weighted $ $ Options outstanding at beginning of year 47,000 4.31 51,500 4.26 Changes during the year: Granted - - - - Exercised - - (4,500 ) 3.74 Forfeited - - - - Expired - - - - Options outstanding at end of year 47,000 4.31 47,000 4.31 Options exercisable at end of year 47,000 4.31 47,000 4.31 Weighted average fair value of options granted during the year $ - $ -
Schedule of Concerning the Options Granted to Non Employees Outstanding	The following table presents summary information concerning the options granted to non-employees outstanding as of December 31, 2023: Range of Number outstanding Weighted Weighted 3.74-5.08 47,000 5.98 4.31
Schedule of Activities for Unvested RSUs Granted to Employees and Directors	The following table summarizes the activities for unvested RSUs granted to employees and directors for the years ended December 31, 2023 and 2022: Year ended 2023 2022 Number of RSUs Outstanding at the beginning of period 1,561,570 801,303 Granted 1,134,000 1,009,600 Issued (574,791 ) (217,333 ) Forfeited (286,417 ) (32,000 ) Outstanding at the end of the period 1,834,362 1,561,570 Vested during the period 521,625 218,000 Vested and unissued at period end 212,136 265,302 Year ended 2023 2022 Number of RSUs Outstanding at the beginning of period 4,000 8,000 Granted - - Issued (4,000 ) (4,000 ) Forfeited - - Outstanding at the end of the period - 4,000 Vested during the period 4,000 4,000 Vested and unissued at period end - -

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Income and Expenses[Abstract]
Schedule of Financial Income	Financial income Year ended 2023 2022 Income from interest on the Senior DIP Loan Agreement and deposits $ 8,016 $ 3,473 Exchange rate differences, net - 176 Income from interest on corporate bonds 10 100 Revaluation of securities, net 16,461 - Other 143 5 $ 24,630 $ 3,754
Schedule of Financial Expenses	Financial expenses Year ended 2023 2022 Exchange rate differences, net $ 124 $ - Bank and broker commissions 29 14 Loss from securities, net - 43 Revaluation of securities, net 69 763 Fees regarding Scilex transaction 1,514 - Interest expenses 2,037 - $ 3,773 $ 820

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2023
Taxes on Income [Abstract]
Schedule of Deferred Income Taxes	Deferred income taxes December 31, 2023 2022 In respect of: Net operating loss carryforward $ 27,757 $ 27,610 Research and development expenses 2,731 5,195 Revaluation of investments (2,611 ) - Other temporary differences 596 - Less - valuation allowance (28,473 ) (32,805 ) Net deferred tax assets $ - $ -
Schedule of Income (Loss) Before Taxes on Income	Income (Loss) before taxes on income and income taxes included in the income statements of operations Year ended 2023 2022 Income (loss) before taxes on income: U.S. $ 11,604 $ (11,164 ) Outside U.S. (6,516 ) (26,500 ) $ 5,088 $ (37,664 ) Taxes on income (tax benefit): Current: U.S. - - Outside U.S. - (100 ) $ - $ (100 )
Schedule of Reconciliation of the Theoretical Tax Expense	Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense: Year ended 2023 2022 Income (loss) before income taxes as reported in the consolidated statement of comprehensive loss $ 5,088 $ (37,664 ) Statutory tax (benefit) expense – 21% 1,068 (7,909 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax (4,332 ) 7,290 Disallowable deductions 731 1,152 Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd. (305 ) (533 ) Prior year true-up 2,838 - Withholding tax, see note 12d above - 100 Uncertain tax position - - Taxes on income for the reported year $ - $ 100
Schedule of Unrecognized Tax Benefits	The following table summarizes the activity of the Company unrecognized tax benefits: Year ended 2023 2022 Balance at Beginning of Year $ 11 $ 11 Decrease in uncertain tax positions for the current year - - Balance at End of Year $ 11 $ 11
Schedule of Valuation Allowance Rollforward	Valuation Allowance Rollforward Period ended Balance at Additions Balance at Allowance in respect of carryforward tax losses: Year ended December 31, 2023 $ 32,805 $ (4,332 ) $ 28,473 Year ended December 31, 2022 26,659 6,146 32,805

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Schedule of Expenses to Related Parties	Balances with related parties: December 31, 2023 2022 Accounts payable and accrued expenses - Shnida $ 160 $ - Accounts payable and accrued expenses - KNRY $ 165 $ 1
Schedule of Expenses to Related Parties	Expenses to related parties: Year ended 2023 2022 KNRY $ 486 $ 800 Shnida 445 146 Nadav Kidron (President and Chief Executive Officer) $ 296 $ 674

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($) $ in Thousands						12 Months Ended
	Sep. 21, 2023	Sep. 08, 2023	Aug. 09, 2023	Jan. 11, 2023	Mar. 18, 2021	Dec. 31, 2023	Dec. 31, 2022	Aug. 07, 2023
Significant Accounting Policies [Line Items]
Capital stock shares issued (in Shares)					1,890,000
Share issued percentage					63%
Exhibited over percentage				1%
Purchase price								$ 105,000
Non refundable closing fee			$ 450
Additional cash paid			5,000
DebtConversionPeriod	18 months
Secured promissory note	$ 101,875
Unpaid interest	875
Loan agreement	$ 1,000
Aggregate borrowing		$ 99,550
Tax benefit						50%
Expected liability						12 years
Recognized revenue aggregate amount						$ 20,382
Recognized amount						1,340
Deferred remaining amount						2,000
Fixed consideration						$ 2,000
Weighted average number of stock options shares (in Shares)						1,227,506
Diluted net loss (in Shares)							3,356,203
Additional period						5 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Lease agreements						1 year
Maximum [Member]
Significant Accounting Policies [Line Items]
Lease agreements						4 years
HTIT License Agreement [Member]
Significant Accounting Policies [Line Items]
Aggregate amount						$ 22,382
DIP Loan Agreement [Member]
Significant Accounting Policies [Line Items]
Principal amount			$ 100,000

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Fair Value Measurement - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Significant Accounting Policies [Line Items]
Marketable securities	$ 110,555	$ 437
DNA [Member]
Significant Accounting Policies [Line Items]
Marketable securities	297	352
Entera [Member]
Significant Accounting Policies [Line Items]
Marketable securities	70	85
Note [Member]
Significant Accounting Policies [Line Items]
Marketable securities	93,066
Transferred Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities	1,440
Closing Penny Warrant [Member]
Significant Accounting Policies [Line Items]
Marketable securities	9,180
Subsequent Penny Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities	6,502
Level 1 [Member]
Significant Accounting Policies [Line Items]
Marketable securities	1,807	437
Level 1 [Member] | DNA [Member]
Significant Accounting Policies [Line Items]
Marketable securities	297	352
Level 1 [Member] | Entera [Member]
Significant Accounting Policies [Line Items]
Marketable securities	70	85
Level 1 [Member] | Note [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 1 [Member] | Transferred Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities	1,440
Level 1 [Member] | Closing Penny Warrant [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 1 [Member] | Subsequent Penny Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 2 [Member]
Significant Accounting Policies [Line Items]
Marketable securities	9,180
Level 2 [Member] | DNA [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 2 [Member] | Entera [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 2 [Member] | Note [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 2 [Member] | Transferred Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 2 [Member] | Closing Penny Warrant [Member]
Significant Accounting Policies [Line Items]
Marketable securities	9,180
Level 2 [Member] | Subsequent Penny Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 3 [Member]
Significant Accounting Policies [Line Items]
Marketable securities	99,568
Level 3 [Member] | DNA [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 3 [Member] | Entera [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 3 [Member] | Note [Member]
Significant Accounting Policies [Line Items]
Marketable securities	93,066
Level 3 [Member] | Transferred Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 3 [Member] | Closing Penny Warrant [Member]
Significant Accounting Policies [Line Items]
Marketable securities
Level 3 [Member] | Subsequent Penny Warrants [Member]
Significant Accounting Policies [Line Items]
Marketable securities	$ 6,502

Short-Term Deposits (Details) -

Short-Term Deposits (Details) - Schedule of Short Term Deposits - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Dollar deposits Amount (in Dollars)	$ 95,279	$ 111,513
Minimum [Member]
Short-Term Debt [Line Items]
Annual interest rate	6.35%	0.93%
Maximum [Member]
Short-Term Debt [Line Items]
Annual interest rate	6.81%	6.81%

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Cost of securities	$ 595	$ 595
Cost method investments	$ 1
DNA [Member]
Marketable Securities [Line Items]
Ownership percentage	1.40%

Marketable Securities (Detail_2

Marketable Securities (Details) - Schedule of Marketable Securities also Included Held to Maturity Securities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Member]
Short-term:
Total Short-term		$ 3,743
Short-Term Debt [Member] | DNA [Member]
Short-term:
Total Short-term		352
Short-Term Debt [Member] | Entera [Member]
Short-term:
Total Short-term		85
Short-Term Debt [Member] | Held-to-Maturity Securities [Member]
Short-term:
Total Short-term		3,306
Long-Term Debt [Member]
Long-term:
Total Long-term	1,807
Long-Term Debt [Member] | DNA [Member]
Long-term:
Total Long-term	297
Long-Term Debt [Member] | Entera [Member]
Long-term:
Total Long-term	70
Long-Term Debt [Member] | Transferred Warrants [Member]
Long-term:
Total Long-term	$ 1,440

Marketable Securities (Detail_3

Marketable Securities (Details) - Schedule of Amortized Cost and Estimated Fair Value of Held-to-Maturity Securities $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Marketable Securities [Line Items]
Amortized cost	$ 3,306
Gross unrealized gains (losses)	(82)
Estimated fair value	3,224
Commercial bonds [Member]
Marketable Securities [Line Items]
Amortized cost	3,258
Gross unrealized gains (losses)	(82)
Estimated fair value	$ 3,176
Average yield to maturity rate	1.07%
Accrued interest [Member]
Marketable Securities [Line Items]
Amortized cost	$ 48
Gross unrealized gains (losses)
Estimated fair value	$ 48

Investments, at Fair Value (Det

Investments, at Fair Value (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 21, 2023	Dec. 31, 2023	Mar. 21, 2025	Dec. 21, 2024	Sep. 21, 2024	Jun. 21, 2024	Mar. 21, 2024	Dec. 21, 2023
Investments, at Fair Value [Line Items]
Aggregate unpaid principal balance amount		$ 7,801						$ 5,000
Exit fee		3,056
Principal payment		$ 5,000
Warrant per share (in Dollars per share)		$ 4.13
Own in excess		9.90%
Warrant expire		Nov. 10, 2027
Fair value transaction		$ 101,875
Short term investment		57,713
Long term investments		$ 35,353
Maximum [Member]
Investments, at Fair Value [Line Items]
Discount rate		52.84%
Fair value transaction		$ 110,188
Minimum [Member]
Investments, at Fair Value [Line Items]
Discount rate		51.92%
Fair value transaction		$ 93,066
Penny Warrants [Member]
Investments, at Fair Value [Line Items]
Warrant per share (in Dollars per share)		$ 11.5
Closing Penny Warrant [Member]
Investments, at Fair Value [Line Items]
Fair value transaction		$ 9,180
Transferred Warrants [Member]
Investments, at Fair Value [Line Items]
Fair value transaction		1,440
Warrant [Member]
Investments, at Fair Value [Line Items]
Fair value transaction		$ 15,638
Forecast [Member]
Investments, at Fair Value [Line Items]
Aggregate unpaid principal balance amount			$ 20,000	$ 20,000	$ 20,000	$ 20,000	$ 15,000
Scilex Holding Company [Member] | Common Stock [Member]
Investments, at Fair Value [Line Items]
Aggregate shares (in Shares)		2,125,000
Scilex Transaction [Member]
Investments, at Fair Value [Line Items]
Aggregate shares (in Shares)	4,000,000
Warrant per share (in Dollars per share)	$ 11.5
Principal of note issued	$ 101,875
Fees added to principal amount	$ 1,000
Bear interest rate	8.50%	50%
Fair value transaction		$ 6,502
Scilex Transaction [Member] | Maximum [Member]
Investments, at Fair Value [Line Items]
Bear interest rate		125%
Scilex Transaction [Member] | Minimum [Member]
Investments, at Fair Value [Line Items]
Bear interest rate		100%
Scilex Transaction [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Investments, at Fair Value [Line Items]
Bear interest rate	4%	15%
Scilex Transaction [Member] | DIP Loan Agreement [Member]
Investments, at Fair Value [Line Items]
Accrued and unpaid interest	$ 875
Scilex Transaction [Member] | Penny Warrants [Member]
Investments, at Fair Value [Line Items]
Aggregate shares (in Shares)	4,500,000
Warrant per share (in Dollars per share)	$ 0.01
Warrant per share (in Dollars per share)		$ 0.01
Scilex Transaction [Member] | Scilex Holding Company [Member] | Penny Warrants [Member]
Investments, at Fair Value [Line Items]
Aggregate shares (in Shares)	8,500,000
Common stock of Scilex, par value (in Dollars per share)	$ 0.0001
Warrant per share (in Dollars per share)	$ 0.01
Transaction expenses	$ 1,910

Other Non-Marketable Equity S_2

Other Non-Marketable Equity Securities (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 26, 2022	Dec. 31, 2023
Other Non-Marketable Equity Securities [Line Items]
Issued and outstanding stock	5%
Recorded an increase in value		$ 824
Series B Preferred Stock [Member]
Other Non-Marketable Equity Securities [Line Items]
Aggregate purchase price	$ 2,700

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of Accounts Payable and Accrued Expenses - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 551	$ 2,175
Payroll and related accruals	453	529
Institutions		11
Accrued liabilities	605	1,443
Total accounts payable and accrued expenses	$ 1,609	$ 4,158

Short-Term Borrowings (Details)

Short-Term Borrowings (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Aug. 08, 2023
Short-Term Borrowings (Details) [Line Items]
Aggregate amount	$ 49,550,000	$ 99,550
Debt repaid	$ 50,000
Minimum [Member]
Short-Term Borrowings (Details) [Line Items]
Interest ranging		6.66%
Maximum [Member]
Short-Term Borrowings (Details) [Line Items]
Interest ranging		7.38%
Israel Discount Bank Ltd.[Member]
Short-Term Borrowings (Details) [Line Items]
Aggregate amount		$ 99,550

Short-Term Borrowings (Detail_2

Short-Term Borrowings (Details) - Schedule of the Aggregate Remaining Annual Principal Payments on Debt Until Maturity - USD ($)	Dec. 31, 2023	Aug. 08, 2023
Schedule Of the Aggregate Remaining Annual Principal Payments on Debt Until Maturity [Abstract]
2024	$ 49,550,000
Total	$ 49,550,000	$ 99,550

Commitments (Details)

Commitments (Details)

1 Months Ended

12 Months Ended

Nov. 13, 2022 USD ($)

Aug. 26, 2022 USD ($)

Jan. 02, 2021 USD ($)

Jan. 02, 2021 ILS (₪)

Jan. 31, 2019 USD ($)

Oct. 31, 2016 USD ($)

Jan. 16, 2016 USD ($)

Mar. 31, 2011 shares

Dec. 31, 2023 USD ($)

Dec. 31, 2023 ILS (₪)

Dec. 31, 2022 USD ($)

Sep. 21, 2023 USD ($)

Feb. 01, 2022 m²

Aug. 21, 2020 USD ($)

Feb. 15, 2011

Commitments [Line Items]

Description of license agreement

According to the HTIT License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”). Pursuant to the HTIT License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

According to the HTIT License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”). Pursuant to the HTIT License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

Milestone payment

$ 20,500,000

Initial payment

$ 3,000,000

Payment obligation

$ 6,000,000

Deferred revenue received

$ 1,340,000

$ 2,000,000

Development and production on capsules

8,971,000

27,639,000

Interest amount

$ 101,875,000

Received Interest amount

2,559,000

Liability

59,000

Management fees

$ 120

₪ 435

120

₪ 435

Additional space (in Square Meters) | m²

264

Expenses related to leases

236,000

264,000

Operating Lease, Cost

267,000

$ 214,000

Attorneys fees

$ 850,000

Aggregate purchase price

$ 2,700,000

Percentage of stock issued

5%

Percentage of stock outstanding

5%

Medicox LicenseAgreement [Member]

Commitments [Line Items]

Development on capsule

$ 15,000,000

Development and production on capsules

$ 2,000,000

Royalties percentage

15%

Israel Innovation Authority [Member]

Commitments [Line Items]

Royalty percentage

3%

Interest amount

$ 2,208,000

Minimum [Member]

Commitments [Line Items]

Lessee, Operating Lease, Discount Rate

3%

Minimum [Member] | Israel Innovation Authority [Member]

Commitments [Line Items]

Royalty percentage

100%

Maximum [Member]

Commitments [Line Items]

Lease payments

5.75%

Maximum [Member] | Israel Innovation Authority [Member]

Commitments [Line Items]

Royalty percentage

150%

DNA [Member] | Entera Bio [Member]

Commitments [Line Items]

Ordinary shares received (in Shares) | shares

117,000

Royalty percentage

3%

8%

Second Milestone Payment [Member]

Commitments [Line Items]

Milestone payment

$ 6,500,000

Third Milestone Payment [Member]

Commitments [Line Items]

Milestone payment

$ 4,000,000

Fourth Milestone Payment [Member]

Commitments [Line Items]

Milestone payment

$ 4,000,000

Fifth Milestone Payment [Member]

Commitments [Line Items]

Milestone payment

$ 3,000,000

Commitments (Details) - Schedul

Commitments (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Line Items]
Operating right-of-use assets	$ 694	$ 987
Operating lease liabilities, current	267	247
Operating lease liabilities long-term	342	647
Total operating lease liabilities	$ 609	$ 894
Operating leases	2 years 6 months	3 years 4 months 28 days
Operating leases percentage	3.15%	3.15%

Commitments (Details) - Sched_2

Commitments (Details) - Schedule of Right-of-Use Assets Over the Remaining Lease - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Schedule of Right-of-Use Assets Over the Remaining Lease [Line Items]
2024		$ 282
2025		222
2026		120
2027		10
Total undiscounted lease payments		634
Less: Interest	[1]	(25)
Present value of lease liabilities		$ 609	$ 894
[1]Future lease payments were discounted by 3%-5.75% interest rate.

Stockholders' Equity (Details)

Stockholders' Equity (Details)							12 Months Ended
	Mar. 06, 2024 USD ($)	Nov. 03, 2021 USD ($) $ / shares shares	Sep. 01, 2021 USD ($)	Jul. 15, 2021 USD ($)	Jan. 02, 2021 USD ($)	Jan. 02, 2021 ILS (₪)	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 ILS (₪) shares	Dec. 31, 2022 USD ($) shares
Class of Stock [Line Items]
Aggregate of common stock, value							$ 2,428,000		$ 11,500,000
Aggregate net proceeds							2,428,000		$ 11,500,000
Fees and expenses					$ 120	₪ 435	$ 120	₪ 435
Exercise price (in Dollars per share) | $ / shares							$ 4.13
Offering expenses [Member]
Class of Stock [Line Items]
Aggregate shares issued (in Shares) | shares		2,000,000
Purchase price per share (in Dollars per share) | $ / shares		$ 25
Fees and expenses		$ 46,375,000
Common Stock [Member]
Class of Stock [Line Items]
Outstanding warrants (in Shares) | shares							20,000
New Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Aggregate of common stock, value				$ 100,000,000
Percentage of commission				3%
Aggregate shares issued (in Shares) | shares									273,997
Aggregate net proceeds									$ 5,129,000
Cantor Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Aggregate of common stock, value			$ 100,000,000
Percentage of commission			3%
Aggregate shares issued (in Shares) | shares							1,971,447	1,971,447
Aggregate net proceeds							$ 26,253,000
Subsequent Event [Member] | Cantor Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Aggregate net proceeds	$ 26,253,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of Warrant Activity - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Warrant Activity [Abstract]
Warrants, Warrants outstanding at beginning of year	150,705	158,375
Weighted- Average Exercise Price, Warrants outstanding at beginning of year	$ 4.71	$ 4.78
Warrants, Issued
Weighted- Average Exercise Price, Issued
Warrants, Exercised		4,200
Weighted- Average Exercise Price, Exercised		$ 4.8
Warrants, Expired	130,705	3,470
Weighted- Average Exercise Price, Expired	$ 4.8	$ 7.81
Warrants, Warrants outstanding at end of year	20,000	150,705
Weighted- Average Exercise Price, Warrants outstanding at end of year	$ 4.13	$ 4.71
Warrants, Warrants exercisable at end of year	20,000	150,705
Weighted- Average Exercise Price, Warrants exercisable at end of year	$ 4.13	$ 4.71

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)								12 Months Ended
	May 01, 2023	Apr. 17, 2023	Sep. 18, 2022	Jul. 28, 2022	May 02, 2022	Jan. 10, 2022	Jan. 03, 2022	Dec. 31, 2023	Dec. 31, 2022	Jan. 09, 2022
Stock-Based Compensation (Details) [Line Items]
Options granted	20,000			34,000	7,500		150,000	1,479,426	1,261,426
Fair value (in Dollars)	$ 49,000						$ 2,084,000
Shares, issued							18,000
Exercise price (in Dollars per share)						$ 12.03	$ 12.03
Options are vested								82,875
Expired terms					May 02, 2032		Jan. 03, 2032
Fair value of options granted (in Dollars)			$ 665,000
Closing market share price (in Dollars per share)	$ 2.45			$ 8.47
Expected dividend yield
Risk-free interest rate
Expected term
Vesting, description								The options will vest in four annual installments as follows: the first installment vested immediately on the grant date and the remaining three installments shall vest on each of December 31, 2022, 2023 and 2024.
Aggregate shares		245,500
Total fair value (in Dollars)		$ 550,000
Stock options								132,000
RSUs forfeited								110,917
Other Selling and Marketing Expense (in Dollars)								$ 663,000
Unrecognized compensation expense (in Dollars)								$ 707,000
Weighted average period								9 months 18 days
Options exercised									4,500
Compensation expenses (in Dollars)								$ 26,000	$ 92,000
Unrecognized compensation costs (in Dollars)								$ 2,693
Common Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							30,000
Fair value (in Dollars)				$ 576,000
Options exercised									39
Director [Member]
Stock-Based Compensation (Details) [Line Items]
Closing market share price (in Dollars per share)			$ 3.91
Expected dividend yield			0%
Expected volatility			52.87%
Risk-free interest rate			3.62%
Expected term			5 years 5 months 26 days
Vesting, description								The options shall vest in four equal annual installments on each of May 2, 2023, 2024, 2025 and 2026.
Options Held [Member]
Stock-Based Compensation (Details) [Line Items]
Expired terms							Jan. 03, 2032
Chief Executive Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							107,000
Market share price (in Dollars per share)							$ 13.89
Board of Directors {Member]
Stock-Based Compensation (Details) [Line Items]
Shares, issued							63,000
Aggregate shares							40,000
Employees shares (in Dollars per share)							$ 2,500
President and Chief Executive Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Shares, issued							42,000
Chief Scientific Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							72,000
Shares, issued							21,000
Chief Operating and Business Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Shares, issued							19,000
Chief Financial Officer and Treasurer [Member]
Stock-Based Compensation (Details) [Line Items]
Treasury shares							19,000
Chief Legal Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Shares, issued										24,000
Chief Legal Officer [Member] | Common Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Shares, issued										1,500
Employees Board Members and Non-Employees [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							321,500
Exercise price (in Dollars per share)							$ 13.89
Expired terms			Sep. 18, 2032
Fair value of options granted (in Dollars)							$ 214,000
Closing market share price (in Dollars per share)							$ 12.03
Expected dividend yield							0%
Expected volatility							63.22%
Risk-free interest rate							1.60%
Expected term							6 years 3 months
Chief Operating and Business Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							36,000
Fair value of options granted (in Dollars)							$ 2,630,000
Closing market share price (in Dollars per share)							$ 13.89
Expected dividend yield							0%
Expected volatility							63.05%
Risk-free interest rate							1.46%
Expected term							6 years 3 months
Chief Financial Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							32,000
Chief Commercial Officer [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted							32,000
Director [Member]
Stock-Based Compensation (Details) [Line Items]
Exercise price (in Dollars per share)					$ 5.14
Closing market share price (in Dollars per share)					$ 5.14
Employees and Directors [Member]
Stock-Based Compensation (Details) [Line Items]
Stock options granted (in Dollars)								$ 811,000	$ 2,662,000
Employees [Member]
Stock-Based Compensation (Details) [Line Items]
Intrinsic value of options exercised (in Dollars)									243,000
Non Employees [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted								47,000
Intrinsic value of options exercised (in Dollars)									24,000
Oravax’s [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted			328,318
Exercise price (in Dollars per share)			$ 3.91
2019 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Reserved pool of shares								7,500,000
Maximum term of the options								10 years
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted		868,500		404,100	4,500		207,500
Fair value (in Dollars)		$ 1,980					$ 2,849
Exercise price (in Dollars per share)					$ 5.14		$ 13.89
Fair value of options granted (in Dollars)					$ 23
Closing market share price (in Dollars per share)		$ 2.28		$ 8.47
Weighted average period								1 year
Compensation expenses (in Dollars)								$ 3,210,000	$ 8,365,000
Black Scholes Option Pricing Model [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value (in Dollars)				$ 3,423,000
Fair value of options granted (in Dollars)					$ 24,000
Expected dividend yield					0%
Expected volatility					65.26%
Risk-free interest rate					3.03%
Expected term					6 years 3 months 3 days
Phantom Share Units (PSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Options granted				175,500
Fair value (in Dollars)				$ 1,486
Closing market share price (in Dollars per share)				$ 8.47

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Fair Value Each Option Grant is Estimated	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation (Details) - Schedule of Fair Value Each Option Grant is Estimated [Line Items]
Expected option life (years)
Expected stock price volatility (%)
Risk free interest rate (%)
Expected dividend yield (%)
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of Fair Value Each Option Grant is Estimated [Line Items]
Expected option life (years)		6 years 3 months
Expected stock price volatility (%)		63.05%
Risk free interest rate (%)		1.46%
Expected dividend yield (%)		0%
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of Fair Value Each Option Grant is Estimated [Line Items]
Expected option life (years)		6 years 3 months 3 days
Expected stock price volatility (%)		65.26%
Risk free interest rate (%)		3.03%
Expected dividend yield (%)		0%

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Stock Options Granted to Employees and Directors - Revenue, Rights Granted [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation (Details) - Schedule of Stock Options Granted to Employees and Directors [Line Items]
Number of options, Options outstanding at beginning (in Shares)	2,041,676	1,942,117
Weighted average exercise price, Options outstanding at beginning	$ 8.47	$ 7.14
Changes during the year:
Number of options, Granted (in Shares)		359,000
Weighted average exercise price, Granted		$ 13.55
Number of options, Forfeited (in Shares)	(132,000)	(48,334)
Weighted average exercise price, Forfeited	$ 14.81	$ 10.59
Number of options, Expired (in Shares)		(144,000)
Weighted average exercise price, Expired		$ 4.08
Number of options, Exercised (in Shares)		(67,107)
Weighted average exercise price, Exercised		$ 5.03
Number of options, Options outstanding at ending (in Shares)	1,909,676	2,041,676
Weighted average exercise price, Options outstanding at ending	$ 8.03	$ 8.47
Options exercisable at end of year (in Shares)	1,479,426	1,261,426
Weighted average exercise price at end of year	$ 7.15	$ 6.86
Weighted average fair value of options granted during the year		$ 7.99

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Summary Information Concerning the Options Granted to Employees and Directors Outstanding - Employees and Directors [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	1,909,676
Weighted Average Remaining Contractual Life Years	5 years 9 months 25 days
Weighted average exercise price $ | $ / shares	$ 8.03
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	857,250
Weighted Average Remaining Contractual Life Years	5 years 10 months 6 days
Weighted average exercise price $ | $ / shares	$ 3.94
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	283,008
Weighted Average Remaining Contractual Life Years	3 years 9 months 18 days
Weighted average exercise price $ | $ / shares	$ 7.96
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding | shares	769,418
Weighted Average Remaining Contractual Life Years	6 years 6 months 7 days
Weighted average exercise price $ | $ / shares	$ 12.62

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of Stock Options Granted to Non Employees Outstanding - Share-Based Payment Arrangement [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation (Details) - Schedule of Stock Options Granted to Non Employees Outstanding [Line Items]
Number of options, Options outstanding at beginning of year	47,000	51,500
Weighted average exercise price, Options outstanding at beginning of year (in Dollars per share)	$ 4.31	$ 4.26
Number of options, Granted
Weighted average exercise price, Granted (in Dollars per share)
Number of options, Exercised		(4,500)
Weighted average exercise price, Exercised (in Dollars per share)		$ 3.74
Number of options, Forfeited
Weighted average exercise price, Forfeited (in Dollars per share)
Number of options, Expired
Weighted average exercise price, Expired (in Dollars per share)
Number of options, Options outstanding at end of year	47,000	47,000
Weighted average exercise price, Options outstanding at end of year (in Dollars per share)	$ 4.31	$ 4.31
Number of options, Options exercisable at end of year	47,000	47,000
Weighted average exercise price, Options exercisable at end of year (in Dollars per share)	$ 4.31	$ 4.31
Weighted average fair value of options granted during the year

Stock-Based Compensation (Det_6

Stock-Based Compensation (Details) - Schedule of Concerning the Options Granted to Non Employees Outstanding - Non Employees [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Stock-Based Compensation (Details) - Schedule of Concerning the Options Granted to Non Employees Outstanding [Line Items]
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit	$ 3.74
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit	$ 3.74
Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding (in Shares) | shares	47,000
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term	5 years 11 months 23 days
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 4.31

Stock-Based Compensation (Det_7

Stock-Based Compensation (Details) - Schedule of Activities for Unvested RSUs Granted to Employees and Directors - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Employees and Directors [Member]
Stock-Based Compensation (Details) - Schedule of Activities for Unvested RSUs Granted to Employees and Directors [Line Items]
Outstanding at the beginning of period	1,561,570	801,303
Granted	1,134,000	1,009,600
Issued	(574,791)	(217,333)
Forfeited	(286,417)	(32,000)
Outstanding at the end of the period	1,834,362	1,561,570
Vested during the period	521,625	218,000
Vested and unissued at period end	212,136	265,302
Non Employees [Member]
Stock-Based Compensation (Details) - Schedule of Activities for Unvested RSUs Granted to Employees and Directors [Line Items]
Outstanding at the beginning of period	4,000	8,000
Granted
Issued	(4,000)	(4,000)
Forfeited
Outstanding at the end of the period		4,000
Vested during the period	4,000	4,000
Vested and unissued at period end

Financial Income and Expenses_2

Financial Income and Expenses (Details) - Schedule of Financial Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Financial Income [Abstract]
Income from interest on the Senior DIP Loan Agreement and deposits	$ 8,016	$ 3,473
Exchange rate differences, net		176
Income from interest on corporate bonds	10	100
Revaluation of securities, net	16,461
Other	143	5
Total Financial income	$ 24,630	$ 3,754

Financial Income and Expenses_3

Financial Income and Expenses (Details) - Schedule of Financial Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Financial Expenses [Abstract]
Exchange rate differences, net	$ 124
Bank and broker commissions	29	14
Loss from securities, net		43
Revaluation of securities, net	69	763
Fees regarding Scilex transaction	1,514
Interest expenses	2,037
Total financial expenses	$ 3,773	$ 820

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Taxes on Income (Details) [Line Items]
Corporate tax rate	21%	21%
Percentage of taxable income	80%
Corporate taxation term	20 years
Israel Tax Authority [Member]
Taxes on Income (Details) [Line Items]
Corporate tax rate	23%	23%
Accumulated tax loss carryforward	$ 102,000	$ 87,000
Oravax Medical Inc [Member]
Taxes on Income (Details) [Line Items]
Accumulated tax loss carryforward	$ 28,000	$ 24,000

Taxes on Income (Details) - Sch

Taxes on Income (Details) - Schedule of Deferred Income Taxes - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Income Taxes [Line Items]
Net operating loss carryforward	$ 27,757	$ 27,610
Research and development expenses	2,731	5,195
Revaluation of investments	(2,611)
Other temporary differences	596
Less - valuation allowance	(28,473)	(32,805)
Net deferred tax assets

Taxes on Income (Details) - S_2

Taxes on Income (Details) - Schedule of Income (Loss) Before Taxes on Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income (loss) before taxes on income:
U.S.	$ 11,604	$ (11,164)
Outside U.S.	(6,516)	(26,500)
Income (loss) before taxes on income	5,088	(37,664)
Current:
U.S.
Outside U.S.		(100)
Taxes on income (tax benefit)		$ (100)

Taxes on Income (Details) - S_3

Taxes on Income (Details) - Schedule of Reconciliation of the Theoretical Tax Expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of the Theoretical Tax Expense [Line Items]
Income (loss) before income taxes as reported in the consolidated statement of comprehensive loss	$ 5,088	$ (37,664)
Statutory tax (benefit) expense – 21%	1,068	(7,909)
Change in the balance of the valuation allowance for deferred tax	(4,332)	7,290
Disallowable deductions	731	1,152
Influence of different tax rate applicable to the Subsidiary and Oravax Medical Ltd.	(305)	(533)
Prior year true-up	2,838
Withholding tax, see note 12d above		100
Uncertain tax position
Taxes on income for the reported year		$ 100

Taxes on Income (Details) - S_4

Taxes on Income (Details) - Schedule of Reconciliation of the Theoretical Tax Expense (Parentheticals)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of the Theoretical Tax Expense [Line Items]
Statutory tax (benefit) expense	21%	21%

Taxes on Income (Details) - S_5

Taxes on Income (Details) - Schedule of Unrecognized Tax Benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Unrecognized Tax Benefits [Line Items]
Balance at Beginning of Year	$ 11	$ 11
Decrease in uncertain tax positions for the current year
Balance at End of Year	$ 11	$ 11

Taxes on Income (Details) - S_6

Taxes on Income (Details) - Schedule of Valuation Allowance Rollforward - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Valuation Allowance Rollforward [Line Items]
Balance at beginning of period	$ 32,805	$ 26,659
Additions	(4,332)	6,146
Balance at end of period	$ 28,473	$ 32,805

Related Party Transactions (Det

Related Party Transactions (Details) ₪ in Thousands						12 Months Ended
	Nov. 01, 2022 USD ($)	Nov. 01, 2022 ILS (₪)	Oct. 31, 2022 USD ($)	Jul. 01, 2008 USD ($)	Jul. 01, 2008 ILS (₪)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)
Related Party Transactions [Line Items]
Consulting fee paid				$ 40
Relocation expenses			$ 331,000
Chief Executive Officer [Member]
Related Party Transactions [Line Items]
Consulting fee paid	$ 27				₪ 146,705
Gross salary						$ 14
Chief Scientific Officer [Member]
Related Party Transactions [Line Items]
Consulting fee paid | ₪					₪ 106,400
President [Member]
Related Party Transactions [Line Items]
Consulting fee paid | ₪		₪ 96,825
Gross salary | ₪							₪ 51,591
Consulting Fee [Member]
Related Party Transactions [Line Items]
Consulting fee paid				$ 29

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Related Parties - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Shnida [Member]
Related Party Transactions [Line Items]
Accounts payable and accrued expenses	$ 160
KNRY [Member]
Related Party Transactions [Line Items]
Accounts payable and accrued expenses	$ 165	$ 1

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Expenses to Related Parties - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
KNRY [Member]
Related Party Transactions [Line Items]
Costs and Expenses, Related Party	$ 486	$ 800
Shnida [Member]
Related Party Transactions [Line Items]
Costs and Expenses, Related Party	445	146
Nadav Kidron [Member]
Related Party Transactions [Line Items]
Costs and Expenses, Related Party	$ 296	$ 674

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Thousands	Jan. 30, 2024	Jan. 22, 2024	Jan. 04, 2024
Subsequent Events [Line Items]
Cash		$ 10,000
Joint venture aggregate amount		$ 20,000
Royalty rate		3%
Common Stock [Member]
Subsequent Events [Line Items]
Cash		$ 10,000
HTIT [Member]
Subsequent Events [Line Items]
Equity interest rate		50%
Joint Venture [Member]
Subsequent Events [Line Items]
Transaction amount		$ 70,000
HTIT [Member]
Subsequent Events [Line Items]
Transaction amount		$ 20,000
Restricted Stock Units (RSUs) [Member] | Three Equal Annual Installments [Member]
Subsequent Events [Line Items]
Aggregate shares (in Shares)			150,000
Fair value of RSU grant			$ 359
Share price (in Dollars per share)			$ 2.39
Restricted Stock Units (RSUs) [Member] | Four Quarterly Installments [Member]
Subsequent Events [Line Items]
Aggregate shares (in Shares)	3,750		37,610
Fair value of RSU grant	$ 11		$ 90
Share price (in Dollars per share)	$ 2.98		$ 2.39
Restricted Stock Units (RSUs) [Member] | Twelve Equal Quarterly Installments [Member]
Subsequent Events [Line Items]
Aggregate shares (in Shares)			950,500
Fair value of RSU grant			$ 2,272
Share price (in Dollars per share)			$ 2.39
Phantom Share Units (PSUs) [Member]
Subsequent Events [Line Items]
Aggregate shares (in Shares)			294,000
Fair value of RSU grant			$ 691